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ABSTRACT 
These days, wide varieties of chemicals are used for the treatment of 
various diseases, which may have different courses in the body. The extent to 
which human population is exposed to different types of medicinal drugs is 
alarming. Chemotherapy is one of various forms of treatment conventionally used 
to combat cancer, during which chemotherapeutic agents enter the bloodstream 
and are distributed throughout the body. Besides targeting cancer cells, 
chemotherapy drugs also react with rapidly dividing cells of certain normal 
tissues. This may lead to any genetic alteration or DNA damage in normal cells. 
Genotoxicity of drugs, routinely used for the treatment of cancer, is of a special 
interest due to the risk of inducing secondary malignancies. 
Present research experimentation is concentrated with genotoxic action of 
cancer chemotherapeutic drugs on human lymphocyte chromosomes in-vitro 
employing cytogenetic assays. Four cancer chemotherapeutic drugs were selected 
for the purpose, namely Idarubicin, Doxorubicin, Cisplatin and Dacarbazine. The 
selected drugs can be categorized under two groups viz. Idarubicin and 
Doxorubicin as anthracycline antibiotics and Cisplatin and Dacarbazine as 
alkylating agents. The parameters used were Chromosomal Aberrations Assay, 
Sister Chromatid Exchange Analysis, Cell Growth Kinetics Assay, Micronucleus 
Assay and Nuclear Division Kinetics. 
The in-vitro short-term tests have the advantage that they can be conducted 
relatively quickly and inexpensively compared to long-term carcinogenicity 
assays. Any change at chromosome level is visualized cytologically viz 
chromosomal aberrations, micronucleus and sister chromatid exchanges etc. 
Assessment of chromosomal aberrations serves as a good indicator of the 
clastogenic effects of tested agents. These are microscopically visible changes in 
chromosome structure and can be categorized as chromosome type and chromatid 
type aberrations. Chromosome type aberrations are caused by damage in cells 
already in Gl or S phase in DNA regions that have not yet been replicated, while 
Chromatid type aberrations are produced by errors in DNA replication in G2 or S 
phase in DNA regions that have already replicated at the time of exposure. Human 
peripheral blood lymphocytes have been shown to be remarkably sensitive 
indicator of induced chromosome structural changes for both in vivo and in vitro 
Studies. 
Sister chromatid exchange assay is a sensitive, rapid and objective method 
of observing reciprocal exchanges between two chromatids. These are cytological 
manifestations of reciprocal exchanges between DNA replication products at 
apparently homologous loci during S phase of cell cycle. Cell cycle kinetics 
analysis is based on the differential staining technique of sister chromatids. It is a 
sensitive method for detecting delay or stimulation in human lymphocyte cultures. 
Micronuclei are formed by the loss of whole chromosome or portion of 
chromosome from daughter nuclei at mitosis and exist separately from main nuclei 
of the cell. Compared to other cytogenetic assays, there are several advantages of 
quantifying micronuclei, including speed and ease of analysis and non-
requirement of metaphase cells. This assay provides the data for the deletion of 
whole or part of the chromosome that may have been lost in chromosomal 
aberration analysis. Cytokinesis Blocked Micronucleus Assay (CBMN Assay) has 
found greatest favor due mainly to its simplicity and lack of uncertainty, regarding 
its effect on base line genetic damage. The nuclear division indices are useful 
parameters for comparing the mitogenic response of lymphocytes and cytostatic 
effects of agents examined in the assay. 
The student's t-test was applied for the chromosomal aberrations, 
micronucleus and sister chromatid exchange assay. The 2 x 3 chi-square test was 
used for nuclear division and cell growth kinetic analysis. The level of 
significance was compared at p < 0.01 and p < 0.001 for all the parameters. 
Doxorubicin is regularly utilized for the treatment of breast cancer. 
Idarubicin (4-demethoxy-daunorubicin) is a synthetic analog of daunorubicin, the 
first generation anthracycline antibiotic. It is recommended primarily for the 
treatment of acute myelogenous leukemia, acute lymphoblastic leukemia in 
children, chronic myelogenous leukemia, myeloblastic syndrome and breast 
cancer. Both the anthracyclines induced significantly increased chromosomal 
abnormalities per cell as well as in the total number of abnormal cells when 
compared with the normal control in the present study. In case of Idarubicin, 
increase in the aberrations was found to be significant in almost all the 
concentrations and exposure duration except for few lower dose concentrations. 
Doxorubicin has earlier been reported to induce chromosomal aberrations in 
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mammalian cells and other topoisomerase II inhibitors such as etoposide, 
mitoxantrone and epirubicin and have also been shown to increase different types 
of structural chromosomal aberrations in Chinese hamster cell lines. One of the 
primary mechanisms, considered to mediate the antiproliferative and cytotoxic 
effects of anthracycline antibiotics, is the inhibition of relegation activity of the 
enzyme topoisomerase II, an enzyme which introduces double strand breaks in 
DNA. 
In the current experimental results, we have reported induction of 
significant increase in the mean sister chromatid exchange frequency by both 
anthracycline at higher concentrations; whereas a significant decrease was 
observed in replication indices corresponding to given concentrations of both the 
drugs. For doxorubicin decline in replication indices was not significant at lower 
concentrations. Our results are in line with previous study which has reported 
induction of sister chromatid exchanges by topoisomerase inhibitors namely 
amascrine, camptothecin, etoposide and nalidixic acid. 
Among the two anthracyclines tested for genotoxicity, idarubicin was found 
to show comparatively higher degree of toxicity and damage to the genetic 
material than doxorubicin in almost every parameter of present research. 
Idarubicin (4-demethoxy-daunorubicin) is a synthetic analog of daunorubicin and 
deletion of the group increases lipophilicity of Idarubicin compared with that of 
doxorubicin and enhances its uptake into cells. This may ultimate increase its 
binding to DNA which may well be attributed to as the possible cause of higher 
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genotoxic outcome. 
Among various types of drugs designed for use in cancer chemotherapy, 
many have the potential for alkylation. Cisplatin is clinically important 
antineoplastic agent with activity against wide spectrum of tumors. It is widely 
used both as single agent and as one of the antineoplastic agents in combination 
therapy. It is a heavy metal complex containing a central atom of platinum 
surrounded by two chloride atoms and two ammonia molecules in cis-position. 
Dacarbazine is an antitumor drug used with considerable success in the 
chemotherapy of a number of neoplasias particularly advanced disseminated 
melanoma, soft tissue sarcomas and Hodgkin's disease. Chemically, dacarbazine 
is designated as 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide. 
In the current experimental work, both of the tested alkylating drugs, 
Cisplatin and Dacarbazine were found to induce considerable increase in 
chromosomal aberrations in-vitro. There was observed a dose dependent increase 
in chromosomal abnormalities per cell as well as in total number of abnormal cell 
counts when compared with normal control. Higher concentration of Cisplatin 
showed significant increase in chromosomal aberration frequency but lower 
concentrations of it did not show any significant effect at any time duration. Our 
study with the platinum drug is in line with earlier studies which have reported 
cisplatin induced chromosomal aberrations and cell killing in Chinese hamster 
ovary cells. Induction of micronuclei and granular chromatin condensation in 
human skin fibroblasts has been observed after cisplatin treatment. 
The platinum antitumor agents are unique coordination complexes and 
cisplatin is the parent compound of this class. It is a known fact that Cisplatin and 
other platinum containing compounds target cellular DNA, forming covalent 
adducts. The most common adducts formed by cisplatin are 1,2-intrastrand 
d(GpG) crosslinks, 1,2-intrastrand d(ApG) crosslinks and minor 1,3-intrastrand 
d(GpNpG) crosslinks but the DNA interstrand crosslinks that represent less than 
1 % of the total platination have often been implicated more as the most cytotoxic 
lesions. 
For dacarbazine also, a greater degree of correlation was observed in 
chromosomal abeiration frequency for all concentrations and durations but only 
higher concentrations of the drug showed high significant increase in aberrations. 
Gaps showed highest contribution, followed by rings and the least was by 
dicentrics. Dacarbazine has earlier been found to induce chromosomal anomalies 
in the form of chromatid breaks and gaps proportional to the dose related rate of 
drug treatment in in-vivo tests, utilizing mouse bone marrow cells. 
Dacarbazine is an imidazole carboxamide derivative with structural 
similarity to certain purines. However, its primary mode of action appears to be 
alkylation of nucleic acids but it also interacts with SH group. The 06-meG is one 
of the most critical events in the mutagenic and carcinogenic effects of most 
alkylating agents including Dacarbazine. 
The overall conclusion that emerged from present results showed that 
application of anthracycline is associated with a significant increase in the 
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incidence of chromosomal abnormalities. Idarubicin showed more profound 
genotoxic effects in all of the cytogenetic assays than doxorubicin. Topoisomerase 
targeting drugs have the potential for both useful effects, in the form of new 
therapeutic agent and harmful effects in the form of mutagenic effects. Delineating 
the mechanism of both the drugs will provide some very fruitfiil results. 
Alkylating agents form an important class of occupational, environmental 
and life style carcinogens and are used in some regimens as among the major 
etiological factors in leukemias. Taking our experimental results into account, both 
of the tested alkylating agents induced genetic damage, showing an important 
increase in sister chromatid exchanges, an induction of chromosomal aberrations 
and micronuclei in cultured lymphocytes. Among alkylating drugs of experiment 
Cisplatin showed slightly higher genotoxic outcome in sister chromatid exchange 
and micronucleus assay than that of Dacarbazine but in chromosomal aberration 
assay towards maximum tested concentration and longer the duration Dacarbazine 
showed more potent effect. Dacarbazine showed little impact on cell cycle and 
nuclear division kinetics especially at lower concentrations. From the experimental 
results and earlier reports, it appears that Cisplatin bring forth an important risk of 
inducing secondary neoplasm in cancer patients receiving this drug. Though 
epidemiological data does not support for the secondary tumor production induced 
by Dacarbazine but its genotoxic effects should not be ignored. 
Chromosomal aberrations are one of the most commonly used biomarkers 
for early detection of risk in exposed populations and are intermediate endpoint in 
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carcinogenesis. Chromosomal instability persists even long after the use of 
anticancer drugs and continuous monitoring is required for the occurrence of 
secondary malignancies. Although most of the agents that induce a significant 
level of sister chromatid exchange, would be carcinogenic and the level of 
exchange may be related to the degree of carcinogenicity, the probability of 
appearance of secondary neoplasm may largely depend on viability of the cells 
affected by the cytotoxicity of the agents. 
More detailed insights into the functioning of these drugs will continue to 
provide new clues for fighting cancer and perhaps to fulfill the promise of 
developing other drugs that will replace them with high efficacy and reduced side 
effects. 
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INTRODUCTION 
Quite a large number of chemicals have become integral part of our routine 
life either in the form of medicines, drugs, dyes, food additives and preservatives, 
or as industrial wastes, pesticides and environmental pollutants. Medicine of late 
has become enriched with powerful pharmaceuticals in the recent decades. The 
extent to which human population is exposed to different types of medicinal drugs 
is alarming. Although much better care of patients has now become available, so 
have much greater harms. Any injury resuhing from medical intervention related 
to a drug is called Adverse Drug Reaction (ADR) (Porta et al, 1999). Between 
2.4% to 6.5% of patients suffer from ADR (Brennan et al, 1991; Bates et al, 
1995; Bates et al, 1997; Classen et al, 1997; Haas et al, 2007), causing 
prolonging of hospitalization by an average of two days (Pirmohamed et al, 
2004). Complicating factors of drug reactions include the myriad clinical 
symptoms and multiple mechanisms of drug-host interaction, many of which are 
poorly understood. Fatal ADRs rank among fourth to sixth leading causes of death 
(Lazarou et al, 1998). Some ADRs are understood, recognized and accepted as 
necessary side effects to achieve the desired benefits, whereas others are due to 
unexpected, unpredictable toxicities. 
Chemotherapy is one of various forms of treatment conventionally used to 
combat cancer, during which chemotherapeutic agents enter the bloodstream and 
are distributed throughout the body. Besides targeting cancer cells, chemotherapy 
drugs also react with rapidly dividing cells of certain normal tissues. This may 
lead to any genetic alteration or DNA damage in normal cells. Thus, genotoxicity 
of cancer chemotherapeutic drugs is of special interest due to the risk of inducing 
secondary malignancies. 
Damage to the genetic material caused by chemicals/drugs is a serious 
problem. This form of damage may interrupt the continuity of genetic information. 
If the damage is unrepaired, it can either lead to death of the cells or to the 
production of mutations. The observation that chromosome damage can be caused 
by exposure to ionizing radiation or carcinogenic chemicals was among the first 
reliable evidence that physical and chemical agents can cause damage to the 
genetic material of eukaryotic cells. 
Carcinogens are the substances that can induce cancer without prior or 
subsequent exposure to other chemical or physical agents. Those chemicals that 
act by way of directly interacting with DNA, cause gene mutation, duplication or 
any other change in chromosome structure or number and are termed as genotoxic 
carcinogens. These act on early stage of multi-step process of carcinogenesis. 
Carcinogens may act directly on DNA without any modification or may be 
converted into a reactive metabolite before they react with DNA. Genotoxic 
carcinogens, probably due to their effect on DNA, usually produce neoplasm in 
more than one target organ and have a short latent period. 
Genotoxicity Assay Systems 
Over past few decades, search is on for appropriate test system for 
mutagenicity and carcinogenicity testing (Committee on Mutagenicity, 2000). All 
the mutational systems available for human biomonitoring have their own features 
and limitations (Albertini et al, 1996; Tates and Lambert, 1999). Long term tests 
employing animal models, though, have given considerable evidence in estimating 
potency of carcinogens, are nevertheless expensive and time-consuming and are 
unable to meet demands for a quick and sure identification of environmental 
carcinogens. In this case, problems also exist for extrapolation of the data from 
animal model to human. The in-vitro short-term tests have the advantage that they 
can be conducted relatively quickly and inexpensively compared to long-term 
carcinogenicity assays. The role of these tests has increased, because of 
accumulating evidence in support of the somatic mutation theory of carcinogenesis 
(Frazier, 1990; Kirkland etal., 2005). 
Among various bacterial manifestations of DNA damage, Ames chose 
mutagenesis as the basis of his pioneering work to develop a test for potential 
carcinogen. The Salmonella mutagenicity test (Ames et al., 1975) along with other 
short term assays has been extensively used to survey a variety of chemicals for 
mutagenic activities. In this test "Back mutations" are measured in specially 
constructed mutants of Salmonella. Ames test has long been used to investigate 
the mutagenic potential of compounds but there appeared a continuous decrease in 
the degree of sensitivity about the Ames testing over a period of time. 
The development of human tissue culture technique in middle of twentieth 
century encouraged the work in the field of human cytogenetics (Moorehead et al., 
I960; Buckton and Evans, 1982). It is advantageous and practical to use short-
term lymphocyte culture for different types of assays. It has become quite feasible 
now to use cytogenetic methods to detect mutagenic potentiality of chemicals at 
biologically significant levels (Kocaman and Topaktas, 2007) and in doing so it is 
easier to consider the complexity of human exposure patterns with various 
interacting factors and modifying responses (lijima and Morimoto, 1991; Speit 
and Schmid, 2006). 
Cytoeenetic Assays 
Some of the recommended cytogenetic testing assays for the in-vitro 
system are Chromosomal Aberration assay, Sister Chromatid Exchange assay and 
Micronucleus assay. Cell Cycle Kinetic and Nuclear Division Kinetics studies are 
as well performed for the purpose. 
Chromosomal Aberration Assay 
Chromosomal aberrations are microscopically visible changes in 
chromosome structure. Technique for the study of chromosomal aberrations in-
vitro is very well-developed. The methodology, classification and scoring of 
structural aberrations and statistical methods have been described (Evans, 1982; 
Mateuca et ah, 2006). The most common cell types examined for aberrations in 
humans is the peripheral lymphocytes. These cells are easily attainable, grow 
readily in culture and large number of metaphases can be obtained. Relatively long 
life of lymphocytes adds to their utility as a suitable cell type for measuring 
radiation exposure. Other cell types could also be used, though there are some 
difficulties associated with acquiring the cells or obtaining sufficient metaphases 
for analysis. 
A comprehensive description for the classification of chromosome 
aberration types is given in Savage (1976) and Bloom (1981). The broadest class 
of structural chromosomal aberrations is based on whether these are formed before 
or after semi-conservative DNA replication and can be classified as chromosome 
and chromatid type aberrations. 
Chromosome Type Aberrations 
Chromosome type aberrations are caused by errors in DNA repair in the 
unreplicated DNA i.e. in cells already in Gi or S phase in DNA regions that have 
not yet been replicated and can be categorized as deletions, symmetrical and 
asymmetrical interchanges. Deletions may be terminal or interstitial. Small 
interstitial deletions may be termed as 'minutes' while larger ones form ring 
structure which is termed as centric or acentric provided, centromere is present in 
the ring or not. Asymmetrical interchanges between chromosomes result in 
dicentric and acentric fragments. Symmetrical interchanges are particularly 
difficult to be observed in conventionally stained preparations, unless it produces 
morphologically very different karyotypes. 
Chromatid Type Aberrations 
Chromatid type aberrations are produced by errors in DNA replication in 
Gj or S phase in DNA regions that have already replicated at the time of exposure 
or by errors in DNA replication on a damaged template. A terminal deletion is a 
distinct displacement of the chromatid fragment distal to the lesion. Chromatid 
type interstitial deletions are not as readily observable as their chromosome type 
counterparts, probably because the small deleted fragment is often separated from 
the deleted chromosome, and is not always observed. Achromatic lesions are non-
staining or very light staining regions of chromosomes present in one chromatid or 
both sister chromatids at identical loci. These are recorded as gaps when non-
staining region is of a width less than that of chromatid. Their frequency should 
not be included in totals for aberrations per cell, since their significance and 
relationship to other true aberration types are still not clear. 
In case of chromatid type exchanges somatic pairing maintains an 
association between the chromosomes involved in the exchange and can be 
observed in mitotic preparations. Triradial, a three-arm configuration can be 
described as the interaction between one chromosome having isochromatid 
deletion and second having chromatid deletion. 
Sister Chromatid Exchange Assay 
Sister chromatid exchanges (SCEs) are cytological manifestations of 
interchanges between DNA replication products at apparently homologous loci. 
These are reciprocal exchanges of DNA segments between sister chromatids at 
identical loci during S phase of cell cycle and appear to be a consequence of DNA 
replication errors, possibly at the replication fork itself (Simpson and Sale, 2006; 
Wilson and Thompson 2007). The assay has been extensively employed to 
evaluate cytogenetic responses to chemical exposures. Excellent dose response 
relationships, for hundreds of chemicals, have been established in a wide variety 
ofin-vitro and in-vivo short-term experiments (Tucker et al, 1993; Bakopoulou et 
al, 2008). Several factors affecting the frequency of SCEs in in-vitro systems 
have been well investigated. These include BrdU concentration (Shiraishi and Li, 
1990; Rodriguez-Reyes and Morales-Ramirez, 2003), cell lines, age of the culture, 
culture conditions etc (lijima and Morimoto, 1986). Incidence of SCEs depends on 
the magnitude of the proliferative characteristics of cultured lymphocytes, such as 
duration of the cell cycle, response to PHA and number of cell passages. 
Cell Cycle Kinetics 
Cell cycle kinetics analysis is based on the differential staining technique of 
sister chromatids. It is a sensitive method for detecting delay or stimulation in 
human lymphocyte cultures. The potentiality of the mutagenic agent and effect on 
the cell is evaluated by analyzing proportion of mitotic cells in their first, second 
and third replication cycles (Tice et al., 1976; Crossen and Morgan, 1977; 
Lazutka, 1991; Calderon-Ezquerro et al., 2007). The rate at which mitosis occurs 
is measured by the mitotic index or replication index. Replication index gives an 
idea about the stimulation of lymphocytes in culture (Hsu et al., 1997; Bakopoulou 
et al., 2008). Any change in mitotic index following drug exposure compared to 
concurrent control, provides information on mito-stimulative or mito-depressive 
activity of the drug. 
Micronucleus Assay 
Micronucleus test was proposed as a simpler and alternative approach to 
assess chromosome damage. Compared to other cytogenetic assays, there are 
several advantages of quantifying micronuclei, including speed and ease of 
analysis and non-requirement of metaphase cells. Micronuclei are formed by the 
loss of whole chromosome or portion of chromosome from daughter nuclei at 
mitosis and exist separately from main nuclei of the cell. Now in-vitro 
micronucleus assay is widely used for biomonitoring studies, genotoxicity testing 
and as a screening tool for pharmaceutical research (Von der Hude et al, 2000; 
Garriott et al, 2002; Lorge et al, 2006). Several methods have been developed 
based on stathmokinetic, flow cytometric and DNA labeling approaches but 
Cytokinesis Blocked Micronucleus assay (CBMN Assay) has found greatest favor 
due mainly to its simplicity and lack of uncertainty, regarding its effect on base 
line genetic damage (Fenech and Morley, 1986; Fenech, 2006). 
Mechanism of Mutagenesis and Carcinoeenesis 
Any chemical change in DNA molecule or alteration in base sequence can 
manifest as a mutation. From studies on chromosomal abnormalities in cancer 
cells, it has been extrapolated that tumor cells may contain upto thousands of 
mutations. Loeb and colleagues proposed the "mutator phenotype hypothesis" 
suggesting that the normal rate of mutation in cells is insufficient to account for 
this large number of muhiple mutations found in cancer cells (Loeb et al, 2003). 
Alteration of a single base in DNA may produce effects on the cell ranging from 
none at all to rapid death, depending upon whether the gene sequence affected is 
undergoing transcription and translation and if so, the resulting changes in peptide 
sequence for which it codes, is functionally important or trivial. Certain kinds of 
mutations result in carcinogenesis because the affected protein is somehow 
involved in growth regulation. Mutation can result in expression of a protein that 
is not normally formed by the cell or of a modified version of a normally 
expressed protein. Alteration in sequence of tumor suppressor genes could also be 
involved. 
Recent evidence on genetic lesions in multiple steps of cancer development 
suggests that DNA damage has a role to play in many stages of oncogenesis 
(Herrero-Jimez et al, 2000). DNA damages are constantly being produced in 
human cells either by endogenous reactive oxygen species or by exogenous 
genotoxic agents. Most known chemical carcinogens react chemically with DNA, 
either directly or as derivatives produced by metabolic activation to chemically 
reactive electrophilic species, which can then form covalent adducts (Singer and 
Grunberger, 1983). Many alkylating agents are reactive electrophiles that attack 
nucleophilic centers in DNA molecule (Hsu et al, 1991). These agents can 
crosslink within the genome or with proteins thereby hampering proper 
transcription or replication. Reaction typically occurs with the phosphate groups 
as well as with DNA bases themselves. The ring nitrogen atoms of purines are 
most reactive. Interactions have been documented at N ,^ N^, O ,^ N^ and C* of 
Guanine; N ' , N ^ N^ and N^ of Adenine; O^ N^ N"* and C^  of Cytosine and O^ and 
O'' of Thymine. In general, there is high correlation between extents of adduct 
formation and carcinogenicity. Alkylating agents are able to react at many sites in 
DNA, in particular at the nitrogen ring and exocyclic oxygen atoms of the 
phosphate intemucleotide linkages (Singer and Kusmierek, 1982; Drables et al, 
2004). 
The mechanistic chain from adducts to cancer is characterized by many 
stochastic processes such as location of adducts in coding DNA; probability of 
mutation in DNA replication; mutations in the critical genes; accumulation of 
mutations in stem cells; induction of clonal growth (Loechler, 1996; Tareshima et 
al, 1999). Mutations in growth controlling genes play an important role in the 
development of cancer (Harris, 1996; Herrero-Jimez et al, 2000; Baird and 
Mahadevan, 2004). Though there may be many details to be filled in and many 
more oncogenes that have yet been identified, the complex connection between the 
introduction of a mutagenic chemical and development of cancer is now beginning 
to be understood. 
Cancer Chemotherapy 
For last half of the century, chemotherapy has played a major role in the 
treatment of cancer. Chemotherapy may be used as the only treatment, or it may 
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be used in combination with other treatments, such as surgery and radiation 
therapy. Chemotherapy works by killing the rapidly dividing cancerous cells. 
Chemotherapy may not be limited to a single drug. Most of the time, it is given as 
a combination of drugs that work together to kill cancer cells. Type of the drug 
recommended is generally based on the type, stage and grade of the cancer. Some 
types of chemotherapy medications which are commonly used to treat cancer 
include: 
1. Alkylating agents 
These medications interfere with the growth of cancer cells by blocking the 
replication of DNA. Alkylating agents form covalent bonds with DNA, RNA and 
protein to form DNA adducts in which a methyl or ethyl group is added to the 
DNA (Thilly and Call, 1986). This added alkyl group in turn inhibits DNA 
replication and correct encoding. DNA adducts are formed at a number of reactive 
sites on nucleotide bases. Common locations include the N and O of Guanme. 
Alkylating agents also act by the formation of cross-bridges and bonds between 
atoms in the DNA. 
2. Antimetabolites 
These types of drugs block the enzymes needed by the cancer cells to live 
and grow and/or alter the synthesis of DNA or RNA. Those antimetabolites, which 
are structural analogues of nucleotides, are incorporated into cell components as if 
they were essential purines and pyrimidines and, as a consequence, disrupt the 
synthesis of nucleic acids (Knobf ef ai, 1984). 
3. Anti-tumor antibiotics 
These antibiotics are different from those used to treat bacterial infections. 
General properties of these drugs include interaction with DNA in a variety of 
different ways including intercalation, DNA strand breakage and inhibition with 
enzyme topoisomerase II (Fischer and Knobf, 1989). Bleomycin apparently binds 
to DNA and results in single strand breaks and double strand scission, thereby 
disrupting DNA synthesis (Fischer and Knobf, 1989). Most of these compounds 
are isolated from natural sources. Anthracyclines of this group are among the most 
important antitumor drugs. 
4. Mitotic inhibitors 
These drugs inhibit cell division by hindering certain enzymes necessary in 
the cell reproduction process. Mitotic spindle inhibitors bind to microtubular 
proteins, a process which halts cell replication at metaphase (ICnobf er al., 1984). 
However at higher concentration, nucleic acid and protein synthesis is suppressed. 
Mitotic inhibitors include the Vinca alkaloids causing single strand breaks in DNA 
and epipodophyllotoxins which impairs the transportation and incorporation of 
nucleosides into RNA and DNA. 
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5. Nitrosoureas 
These medications impede enzymes that repair DNA. Nitrosoureas appear 
to function as alkylating agents, as well as through other mechnisms such as 
carbamylation. Nitrosoureas are highly lipophilic, which allows them to readily 
cross the lipophilic membranes such as those found in the central nervous system 
andskin(Knobfe/a/., 1984). 
Besides, drugs belonging to above mentioned categories, some hormones 
related drugs are also used to treat tumors. These agents either exert a 
corticosteroid effect or manipulate the hormone environment in hormone 
responsive tumors. For example, the anti androgenic agent flutamide, used to treat 
prostrate cancer, is believed to block androgen receptor sites (Fischer and Knobf, 
1989). 
Side Effects of Cancer Chemotherapy 
One major disadvantage of chemotherapy drugs is their side effects. Some 
of these side effects are short term or temporary and others may be long term. 
Temporary side effects include hair loss, dry mouth, mouth sores (stomatitis), 
difficult or painful swallowing (esophagitis), nausea, vomiting, diarrhea, 
constipation, fatigue, bleeding, susceptibility to infection, infertility, loss of 
appetite, changes in the way food tastes, cognitive impairment, sometimes 
referred to as chemo-brain-liver damage and renal lesions (Herman et ai, 2004; 
de Jong et ai, 2006; Tangpong et ai, 2006). Some of them have been reported to 
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be skin and mucous membrane irritants (Knowles and Virden, 1980). In animal 
models and patient populations, various antineoplastic drugs have been 
associated with myocardial or cardiac conduction defects, atrial fibrillation, 
pulmonary fibrosis, gastrointestinal disturbances, neurotoxicity and 
myelosuppression (Tan et al, 1987; McCarthy and Skillings, 1992; Theile and 
Kemper, 1998; Donzelli et al, 2004; Ferraresi et al, 2006). Although long-term 
side effects are rare, yet these have been experienced by patients long after the 
treatment. Long-term side effects may be any of the following i.e. organ damage, 
including problems with heart, lungs and kidneys, nerve damage and blood in the 
urine (hemorrhagic cystitis). An array of adverse reproductive outcomes has been 
observed in laboratory animals and in the patient populations, who have 
undergone chemotherapy. Follow up studies have also reported increased risk of 
birth defects in the offspring of female-patients (Bar et al, 2003) and male-
patients (Green et al, 1991). In addition, ovarian failure and 
azoospermia/oligospermia have been associated with cancer chemotherapy. 
The nurses and pharmacists face a variety of potential hazards from 
contact with pharmaceuticals. A statistically significant association between fetal 
loss and the occupational exposure of nurses to anticancer drugs has been 
observed in several studies (Selevan et al, 1985) but not in other (Stucker et al, 
1990). Light headedness, dizziness, nausea, headaches, skin and mucous 
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membrane reaction, hair loss, cough and allergic reactions have been reported by 
nurses handling antineoplastic drugs (Crudi, 1984). 
REVIEW OF LITERATURE 
Cancer Chemotherapeutic drugs: Mutasenicitv, Clastosenicitv and 
Carcinosenicity 
Numerous chemotherapeutic drugs have been found to be carcinogenic in 
animal models and many among them have gained attention because of their 
long-term toxicity and mutagenic activity. When given in therapeutic doses, 
many chemotherapeutic drugs have been associated with an increased incidence 
of malignant tumors that develop later (lARC, 1987; Holm, 1990). Thus, it is of 
utmost importance that a method be devised to assess the mutagenic and 
carcinogenic effects of these agents in the human population. Many 
antineoplastic drugs have been reported to be teratogenic and carcinogenic in 
animal models. Vinca alkaloids have been observed to induce genetic toxicity, 
causing increase in the incidence of mutational events, as well as in somatic 
recombination (Gonzalez-Cid et al, 1999; Tiburi et al, 2002). Variations in 
genes are known to influence not only toxicity, but also efficacy of 
chemotherapeutics. The majority of current pharmacogenetic studies focus on 
single enzyme deficiencies as predictors of drug effects; however effects of most 
anticancer drugs are determined by the interplay of several gene products. These 
effects are polygenic in nature (Mladosievicova et al, 2007). 
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The effects of cancer chemotherapeutic agents have been examined 
concurrently in normal and tumor cell populations in vitro, using cytogenetic 
assays (Padjas et al., 2005). Various studies on sister chromatid exchanges and 
chromosomal aberrations resulting from different therapeutic agents have been 
published (Parkes et al., 1985; lijima and Morimoto, 1991; Fantini et al., 1998; 
Kopjar et al., 2002). It has been determined that the rate of SCEs depends upon 
the type of therapy, the specific chemotherapeutic regimen, the mode of therapy 
and the time sequence between the administration of cytotoxic drugs and 
sampling times. 
Indications that chemotherapy may be associated with second 
malignancies are initially reported in case reports and case series and in follow-
up studies of cancer patients undergoing therapy. These reports are strongly and 
consistently associated with the development of leukemia and myelodysplastic 
syndromes (Chak et al., 1984; Quesnel et al., 1993; Boivin et al., 1995). Case 
series and longitudinal studies have also specifically implicated the drug 
cyclophosphamide and chlomaphazine with the development of bladder cancer 
(Baker et al., 1987). Numerous such case reports of new cancers arising in 
patients treated with cancer therapy have appeared in literature since last two 
decades (Tucker et al., 1987; Beck, 2002; Kantidze and Razin, 2007). Aggressive 
and multimodal treatments of Hodgkin's disease have led to dramatic increase in 
survival, though not without significant early toxicity and late complications. The 
most serious late complication is the development of a secondary neoplasm. 
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These secondary cancers include acute nonlymphocytic leukemia, non-Hodgkin's 
lymphoma and various solid tumors (Tucker et al, 1988; Zarrabi and Rosner, 
1989). Malignant chemotherapy has considerably improved the profile of 
patients with Small Cell Lung Cancer (SCLC) and is now accepted as a preferred 
treatment (Aisner et al, 1982). However, several cases of leukemia and other 
neoplasm following intensive chemotherapy for SCLC have also been reported 
(Chakera/., 1984). 
High incidences of chromosomal aberrations have been found in nurses 
and pharmacy personnel, who handled antineoplastic drugs (Sessink et al, 1994). 
Cancer outcomes in healthcare workers, potentially exposed to anticancer drugs, 
have been evaluated in analytical studies. A nurse was reported to develop 
Hodgkin's disease, followed by acute myelogenous leukemia and other case 
diagnosed with chronic myelogenous leukemia (Skov et al, 1992). Another case 
report of bladder cancer in health care workers has been identified in literature 
with no other possible risk for cancer, except exposure to chemotherapeutic 
drugs (Levin et al, 1993). 
Cytosenetic Studies in Human Neoplasias 
There is clear association between chromosome rearrangement and cancer 
occurrence (Bonassi et al, 2000). Chromosomal abnormalities are frequently 
observed in lymphoma patients. All tumors contain structural chromosome 
rearrangement and at least for leukemias, there is a relationship between the 
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number and type of rearrangement and clinical prognosis (Mitelman, 2000; Bayani 
et al, 2005). The most frequently identified chromosomal abnormalities include 
the gain or loss of whole chromosome or duplication or of a portion thereof and 
also translocations or other structural rearrangements (Schatzkin et al, 1990; 
Mitelman et al, 1997). The diversity of various abnormalities clearly implies that 
different mechanisms of genetic change are responsible for the development of 
malignancies. The gain of a complete or partial chromosome clearly suggests the 
amplification of genes, resuhing in an increase of gene products which is an 
important factor in malignant process. 
The first milestone in the development of human tumor cytogenetics was 
set by Nowell and Hungerford (1966), who discovered the first specific 
chromosomal anomaly in human chronic myeloid leukemia, which was called 
'Philadelphia' chromosome. Later it was found to be a case of translocation. In 
addition, various translocations have been observed with more than two or three 
chromosomes involved (Verma and Macera, 1987). Almost all acute non-
lymphocytic leukemia (ANLL) actually presents detectable cytogenetic changes. 
Point mutations are relatively common in acute myelogenous leukemia (Collins et 
al, 1989). The major abnormalities found in acute-lymphoblastic leukemia are 
translocations involving various chromosomes. Approximately 75-100% of the 
cases of acute nonlymphocytic leukemia have some or other type of chromosomal 
abnormality (Testa et al, 1985). Nearly all non-Hodgkin Lymphoma patients have 
specific non-random chromosomal abnormalities. Burkitt's lymphoma is the 
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second neoplasm that has been extensively characterized and involves 
translocation. In chronic lymphocytic leukemia and small lymphocytic leukemia, 
chomosomal abnormalities include trisomy, inversions and translocations 
(Tsujimotoe^a/., 1984). 
Many types of chromosomal changes have been related to specific cancers, 
for example, in case of colorectal tumorigenesis, it has been shown that 10-15 % 
of sporadic colorectal cancers exhibit microsatellite instability and nucleotide 
substitution due to mismatch repair deficiency (Jacob et al, 2001). However, the 
remaining 85% are due to large number of gross chromosomal changes. This 
chromosomal instability is observed as early as in very small adenomas (Shih et 
al, 2001). Through specific selective advantage and clonal expansion, this 
instability may give rise to neoplastic cells. In the follow up studies (Bonassi et 
al, 1995; Bonassi et al, 2000), relationship between chromosomal aberration and 
cancer development has been strengthened. The subjects who had historically 
increased levels of chromosomal aberration were found more likely to develop 
cancer than those registered with low levels of chromosomal aberrations. 
OBJECTIVES 
Present research experimentation is concentrated on genotoxic action of 
cancer chemotherapeutic drugs on human lymphocyte chromosomes. Four 
cancer chemotherapeutic drugs were selected for the purpose, namely Idarubicin, 
Doxorubicin, Cisplatin and Dacarbazine. The selected drugs can be categorized 
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under two groups viz. Idarubicin and Doxorubicin as anthracycline antibiotics 
and Cisplatin and Dacarbazine as allcylating agents. The work has been done 
with a view to study the following objectives: 
1. To study the in-vitro genotoxic effects of selected cancer 
chemotherapeutic drugs on human lymphocyte chromosomes using 
peripheral blood lymphocyte culture assay 
2. To analyze the in-vitro induction of sister chromatid exchanges by 
selected cancer chemotherapeutic drugs, employing peripheral blood 
lymphocyte culture assay 
3. To examine the in-vitro effect of selected cancer chemotherapeutic 
drugs on cell cycle kinetics and replication index using peripheral blood 
lymphocyte culture assay 
4. To study the in-vitro micronucleus induction of micronuclei by selected 
cancer chemotherapeutic drugs employing cytochalasin blocked 
micronucleus assay 
5. To study the effect of selected cancer chemotherapeutic drugs on 
nuclear division index and nuclear division cytotoxicity index 
employing cytochalasin blocked micronucleus assay 
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MATERIALS 
AND 
METHODS 
In the present investigation, selected anticancer drugs were tested for 
cytogenetic evaluation on human peripheral blood lymphocyte chromosomes. The 
parameters used are chromosomal aberrations, sister chromatid exchange, cell 
growth kinetics, micronucleus and nuclear division kinetics. 
Description of Test Chemicals 
In the current research assignment, four cancer chemotherapeutic drugs 
were selected namely Idarubicin, Doxorubicin, Cisplatin and Dacarbazine to 
analyze their in-vitro genotoxic action on human lymphocyte chromosomes. Drugs 
belonged to two distinct categories among antineoplastic therapeutics viz. 
anthracycline antibiotics and alkylating agents. Anthracyclines have originally 
been isolated from Streptomyces species and since then are commercially used as 
anticancer drugs. Among selected drugs, doxorubicin is one of the first antibiotics 
isolated, while Idarubicin is a synthetic analog. Alkylating agents also form a vast 
family among antineoplastic drugs. Both the selected alkylating agents, Cisplatin 
and Dacarbazine, are presently under use with considerable success in the field of 
cancer chemotherapy. 
IDARUBICIN 
General Properties: 
Molecular Formula : C26H27NO9 
Molecular weight : 497.494 
Common Trade Name : Idamycin® 
Classification : Antitumor antibiotic 
Idarubicin is an anthracycline analogue of daunorubicin. It is more potent 
and less cardiotoxic than parent drug. It is made available as orange-red, sterile 
and lyopholized powder for reconstitution. 
'. - > 
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Idarubicin 
Indications: 
Idarubicin has been reported to circumvent multi-drug resistance (Berman 
and McBride, 1992) and is primarily used against leukemias like acute 
lymphocytic leukemia, acute non-lymphocytic leukemia, chronic myelogenous 
leukemia and Non-Hodgkin's lymphoma (HoUingshead and Faulds, 1991). 
Idarubicin has also been shown to have its utility in the treatment of breast cancer 
and acute myelogenous leukemia (Pronzato et al. 1991; Hande, 1998). 
DOXORUBICIN 
General Properties: 
Molecular Formula :C27H29NOii. HCl 
Molecular Weight :579.98 
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Common Trade Name : Adriamycin 
Classification : Anthracycline antineoplastic antibiotic 
Doxorubicin is cytotoxic anthracycline antibiotic isolated from the cultures 
of Streptomyces peucetius. Doxorubicin consists of a naphthacenequinone nucleus 
linked through a glycosidic bond at ring atom 7 to an amino sugar, daunosamine. 
It is supplied as sterile, preservative free, orange-red colored powder which can be 
reconstituted for usage. Formulation contains hydrochloric acid for pH adjustment. 
Solution reacts with aluminium producing darker color solution or even 
precipitate. 
0 OH 
H3CO 0 OH 
NH2 -HCI 
Doxorubicin 
Indications: 
Doxorubicin is commonly used to treat Hodgkin's disease, breast cancer, 
soft tissue sarcoma, Kohler's disease (multiple myeloma) and recurring instances 
of ovarian cancer (Macpherson et al., 2006). Doxorubicin is one of the primary 
agents utilized in the treatment of breast cancer (Ibrahim et al., 2003; Minisini et al., 
2008). 
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CISPLATIN 
General Properties: 
Molecular Formula 
Molecular Weight 
Common Trade Name(s) 
Classification 
Pt (NH3)2Cl2 
300.05 
Platinoid); Platinol-AQ®, 
Platinum compound 
Pt 
Cisplatin 
Cisplatin is yellow-colored crystalline powder. It is a heavy metal complex 
containing a central atom of platinum surrounded by two chloride atoms and two 
ammonia molecules in cis-position. This chemical compound is incompatible with 
oxidizing agents and aluminium. Cisplatin reacts with aluminium and becomes 
inactivated permanently. It is, therefore, not administered with aluminium hubbed 
needles. Cisplatin may react with sodium bisulfite and other antioxidants 
Indications: 
Cisplatin is clinically important antineoplastic agent with activity against 
wide spectrum of tumors (Wong et al., 2002). It is widely used both as single 
agent and as one of the antineoplastic agents in combination therapy (Gralla et al., 
1981). It is routinely used for treatments of testicular, ovarian, lung, bladder, 
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cervical, head and neck carcinomas, advanced bladder carcinoma, adrenal cortex 
carcinoma and breast cancer (Rosenberg et al, 1999). 
DACARBAZINE 
General Properties: 
Molecular Formula 
Molecular Weight 
Common Trade Name 
Classification 
N 
: CfiHioNfiO 
: 182.18 
:DTIC 
: Alkylating Agent 
0 
II 
C-NHo 
I 
^^. N^N-NCHj 
H 
Dacarbazine 
Dacarbazine for injection is found as colorless to ivory-colored solution 
which is light sensitive. Each vial contains dacarbazine (as active ingredients), 
citric acid monohydrate and mannitol. Injection is reconstituted and administered 
intravenously. Chemically, dacarbazine is designated as 5-(3,3-dimethyl-l-
triazeno)-imidazole-4-carboxamide. 
Indications: 
Dacarbazine is an antitumor drug used with considerable success in the 
chemotherapy of a number of neoplasias, particularly in case of advanced 
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disseminated melanoma, soft tissue sarcomas and Hodgkin's disease (Connors, 
2005; Tawbi and Kirkwood, 2007). Dacarbazine is given both as single agent and in 
combination with various chemotherapeutic drugs. It is also given for palliative 
therapy of metastatic malignant melanoma. 
Description of Control Chemicals 
Positive Control 
For the whole experimental procedure, cyclophosphamide was used as 
positive control. It is known to have strong mutagenic effects which have since 
been proved many times in different cell types. Cyclophosphamide acts by 
forming DNA-crosslinks by the reaction of chloroethyl moieties of it with adjacent 
nucleotide bases. Due to its potent mutagenic and clastogenic nature, it is widely 
used as positive control in in-vitro assays. 
Negative Control 
In the present investigation the test chemicals are water-soluble; hence 
cultures without any test chemicals were used as negative control. Negative 
control provided the baseline for the comparison of the data to calculate the 
significant effects. 
Chromosomal Aberration Assay 
Human peripheral blood lymphocytes have been shown to be remarkably 
sensitive indicator of induced chromosome structural changes for both in vivo 
(Evans et al, 1979; Evans, 1982) and in-vitro studies (Dhillon et al, 1995). 
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Lymphocytes offer several advantages as a test system viz. easy availability of 
large numbers of human cells, longer life and virtually all the peripheral blood 
lymphocytes are a synchronized cell population in the same GQ or Gi stage of 
mitotic interphase. Further, lymphocytes can be stimulated by mitogens to undergo 
mitosis in culture. 
Preparation of Culture Media 
Culture media from RPMI-1640 supplemented with L-glutamine (GIBCO, 
BRL) was used for the lymphocyte culture. Stock medium was prepared by 
dissolving 10 gms of powder in 1000 ml of autoclaved double distilled water. 
Medium was maintained at pH 7.2 with the help of NaHCOs. Working medium 
was prepared by supplementing medium with 10% foetal calf serum (GIBCO, 
BRL) and 1% antibiotic and antimycotic solution (GIBCO, BRL). It was then 
filtered with millipore (0.22 |iM) and kept at 4 °C in autoclaved bottles for further 
use. Preparation of culture media and working media was done under sterile 
conditions in the laminar flow cabinet. 
Blood Samples 
For each experiment peripheral blood sample by venipuncture was taken 
from healthy donors. It was confirmed in advance that the donors are 
occupationally not exposed to any sort of mutagen. The blood was taken fresh 
every time using needles (21 gauge) and disposable syringes (DispoVan). Heparin 
27 
was used as anticoagulant. The blood was collected in round bottom glass vials 
which were tightly capped after gentle mixing and stored at 4°C for further use. 
Lymphocyte Culture 
Cultures were planted in previously cleaned and sterile chamber of laminar 
flow. All the necessary apparatus (culture vials, pipettes etc.) were sterilized 
before use by autoclaving. Human blood lymphocyte cultures were carried out by 
adding 0.2 ml of whole blood into 5 ml of working culture medium. Lymphocyte 
culture was performed for the study of chromosomal aberrations employing the 
protocol by Dean and Danford (1984). Phytohaemagglutinin (10 )ig/ml; GIBCO, 
BRL) was used to induce mitosis in lymphocytes. 
Different concentrations were tested from 0.001 to 2.0 |ig/ml for three 
exposure durations viz. 24 hr, 48 hr and 72 hrs (V\ 2"^ and 3'^ '' cell cycle) as per the 
protocol to get an insight into the fact that how drug will react to genetic material 
when exposed for longer duration. All the concentrations of the drugs were added 
to the cultures at 0, 24 and 48 hours after the initiation of cultures for 72, 48 and 
24 hours of exposures respectively. Negative and positive control 
(Cyclophosphamide treated) cultures were also simultaneously set for all treatment 
durations. 
The culture vials were gently shaken to mix their contents, and were 
incubated at 37°C in dark for 72 hours. Colchicine (0.2 |.ig/ml) was added to the 
culture 90 minutes prior to harvesting to arrest the cells at metaphase stage. After 
colchicine treatment, the culture vials were taken out from the incubator, gently 
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shaken to mix their contents and the material was then transferred to 15 ml 
centrifuge tubes. The cells were spun by centrifugation (10 minute, 1200 rpm) and 
the supernatant discarded. Pre-warmed hypotonic solution (0.56% KCl) was added 
to the centrifuge tubes, while shaking continuously with the help of a cyclomixer. 
Hypotonic treatment was carried out for 20 minutes at 37°C and the cells were 
recollected by centrifugation. The cell pellets were suspended in 7 ml freshly 
prepared chilled fixative (Methanol (3): Acetic Acid (1)) which was added drop by 
drop with a pasteur pipette while continuously shaking the pellet on the 
cyclomixer so as to avoid formation of clots. In order to ensure proper fixation, the 
cells were kept suspended in the fixative for a maximum period of one hour but 
preferably overnight. The cells were washed thrice with fresh fixative before 
preparing the slides. 
Slide Preparation and Staining 
After the final washing of the cells in the fixative, the cells were 
resuspended in about 0.5 ml of fresh fixative. Two to three drops of this cell 
suspension were put on clean, grease free, chilled and wet micro-slides which then 
were quickly air dried. One day old slides were stained in 5% Giemsa in 
phosphate buffer for 10 minutes. Slides were rinsed in distilled water and dried 
before study. 
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Evaluation of Chromosomal Aberrations 
Metaphase preparations were analyzed for all types of chromosomal 
aberrations and the observations were recorded on a score sheet. In order to avoid 
bias in scoring of the chromosomal anomalies, all slides were coded prior to 
scoring. A total of 100 well spread metaphases were analyzed for each 
concentration of the drug and time duration to analyze various chromosome and 
chromatid type aberrations. Whilst statistical analysis is generally performed on 
combinations of aberration types, it is important to record the complete 
information for each observed aberration, because different types can provide 
additional information. There are many published classification schemes for 
chromosomal aberrations, and good examples can be found in Savage (1975) and 
Bloom (1981) and IAEA technical report series No. 260 (1986). In the present 
study, the same classification scheme has been followed. 
/. Chromatid type aberrations 
The apparent unit of involvement in a chromatid type aberration is, in most 
cases, the single chromatid. The examination of the chromatid type aberrations 
considered the following parameters. 
1. Achromatic lesions (Gaps) 
Achromatic lesions are non-staining or very light staining regions of 
chromosomes present in one chromatid or both sister chromatid at identical 
loci. These are recorded as gaps when non-staining region is of a width less 
than that of a chromatid. 
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2. Terminal deletions 
A terminal deletion is a distinct displacement of the chromatid fragment 
distal to the lesion. The width of non-staining region between the centric 
and acentric fragment is generally greater than the width of chromatid. 
3. Interstitial deletions 
A deletion is observed within the chromatid arm when the width of region 
is more than the width of chromosome 
4. Triradials (Isochromatid and Chromatid deletions) 
A three-arm configuration can be described as the interaction between one 
chromosome having isochromatid deletion and the second having 
chromatid deletion. 
//. Chromosome type aberrations 
Aberrations that involve both chromatids of a chromosome at visibly similar 
loci are termed as chromosome type aberrations. Analysis of chromosomal 
aberrations include following parameters: 
1. Terminal deletions 
Terminal deletion is a distinct displacement of both the chromatid 
fragments of a chromosome distal to the lesion. All paired acentric 
fragments are classified as terminal deletions. 
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2. Interstitial deletions 
Small interstitial deletions, which appear like dots, are simply classified as 
"minutes". 
3. Asymmetrical interchanges 
Asymmetrical interchanges between chromosomes result in dicentric and 
acentric fragments. A cell with two acentric fragments, by convention, is 
classified as a 'dicentric' and a 'terminal deletion'. 
4. Asymmetrical interchange 
Interstitial deletions, in which there is a clear space in center of the ring, are 
termed as "acentric rings". Large interstitial deletions, which carry 
centromeres with them and form a ring, are termed as centric rings. 
Multiple Anomalies 
1. Polyploidy: Increase in the chromosome number in excess of diploid set in 
multiple of the haploid number. 
2. Endoreduplications: The chromosome reduplication occurring in the 
absence of sister chromatid separation. 
3. Cells with multiple anomalies: The cells with 10 or > 10 aberrations. 
Sister Chromatid Exchanse Assay 
Sister chromatid exchange assay is a sensitive, rapid and objective method 
of observing reciprocal exchanges between sister chromatids. This method 
depends upon the phenomenon of 5-bromo-2-deoxyuridine (BrdU), an analogue of 
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thymidine and its incorporation into DNA in place of thymidine. After two rounds 
of cell division the chromatids are labeled with BrdU and consequently get 
differentially stained with Hoechst stain. The BrdU incorporation quenches the 
fluorescence of fluorochrome Hoechst 33258. Therefore, light energy is absorbed 
but not emitted by such dyes which result in the reduced staining of chromatid 
with giemsa. (Stokke and Steen, 1986; Latt, 1976). 
Labeling of Chromosomes 
Sister chromatid exchange analysis was carried out following the standard 
Procedure of Latt et al, (1981) with suitable modifications. The cells in the 
cultures were exposed to BrdU after 24 hours of initiation of cultures, at the final 
concentration of 2 |ig/ml. The culture vials were tightly capped and covered with 
tin foil to avoid light exposure and incubated at 37°C in the dark. After 48 hours 
of the initiation of cultures, different selected doses (from 0.001 to l.Ong/ml) of 
each of anticancer drugs were added into these cultures. The culturing was further 
continued for 24 hours. Positive and untreated controls were also simultaneously 
planted. 
Slide Preparation and Staining 
After 90 minutes of colchicine treatment, the cultures were harvested and 
processed following the same procedure as described for the chromosomal 
aberration analysis. The methods of Latt et al., (1981), with slight modifications, 
were followed for the differential staining of SCEs. One day old slides were 
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dipped in 0.5 |ig/ml of 33258 Hoechst stain dissolved in phosphate buffer saline 
(PBS) in horizontal couplin jar. The slides were rinsed twice in PBS. The air-dried 
slides were then put in flat glass dish with the layer of cells facing upwards. These 
were covered with phosphate buffer (pH 6.8) and exposed to UV lamp (5W, 254 
nm Philips) from a distance of about 15 cm for 30 minutes. The slides were taken 
out from the buffer, washed twice in double distilled water and then incubated in 
2XSSC buffer (0.3M sodium chloride, 0.3M sodium citrate, pH 7.0) at 65°C in 
water bath for 15 minutes using vertical couplin jars. The slides were taken out 
and rinsed in distilled water. The air dried slides were then stained in 3% Giemsa 
for 15 minutes and again rinsed in distilled water. 
All slides were coded prior to scanning so as to avoid any confusion. 
About 50 second-division metaphases with differentially stained chromatids were 
scored for each drug treatment. The interstitial exchanges between two sister 
chromatids were scored as two exchanges and the terminal exchanges were scored 
as a single exchange. Student's t test was applied for calculating the significance of 
difference between the treated and the controls. 
Cell Cycle Kinetics 
The cells undergoing first (Mi), second (M2) and third (M3) division were 
detected by studying the BrdU labeled differentially stained chromosomes 
following the methodology of Tice et al, (1976) and by Crossen and Morgan, 
(1977). The cells with both the chromatids being darkly stained were scored as M] 
cells while those with one dark and one lightly stained chromatids as M2 cells, and 
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those having mixture of both the differentially stained and uniformly stained 
chromatids were scored as M3 metaphases. About 100 well-spread metaphases 
were scored for each concentration and each treatment duration. The replication 
index (RI) was calculated according to the formula of Tice et al. (1976) as given 
below. 
RI = (MiX 1) + (M2X 2) + (M3X 3) /100 
The deviations from the controls were determined by using Chi-Square test. 
Cvtochalasin Blocked Micronucleus Assay 
Cytokinesis blocked micronucleus assay was performed as per the protocol 
of Fenech (2000). About 0.2 ml of whole blood was added to 4.5 mi of culture to 
culture medium supplemented with foetal calf serum and antibiotic-antimycotic 
solution. Phytohaemagglutinin was added at the time of initiation. For 
micronucleus assay drug treatment was given 24 hour after initiation of culture. 
Dose concentrations for both the drugs remained the same as of sister chromatid 
exchange assay experiment. After 44 hour of PHA stimulation, 4.5 |.ig/ml of 
cytochalasin-B was added to the culture and 28 hour after the addition of 
Cytochalasin-B, cells were harvested by centrifugation. The cells were then 
hypotonically treated for 5 minutes and fixed. Slides were prepared by air-drying 
method and examined at 1OOOX. 
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Assessment of Micronucleus Frequency 
Scoring of micronucleus was done as per the criteria accepted at the 
Washington International Workshop on genotoxicity test procedures (Kirsch-
Volders et al, 2000). Micronuclei were scored in binucleated cells only. About 
two thousand cells were analyzed per concentration for each drug. The two nuclei 
in a binucleated cell should have intact nuclear membrane and should be situated 
within same cytoplasmic boundaries. They should be approximately of equal size, 
staining pattern and intensity. The diameter of micronuclei in human lymphocytes 
usually varies between 1/16'^  and 1/3"* of the mean diameter of main nuclei. These 
should have the same color and intensity as that of the main nuclei. 
Nucleoplasmic Bridge 
Nucleoplasmic bridges are a continuous link between the two nuclei in a 
binucleated cell and are thought to arise due to dicentric chromosome in which 
centromeres are pulled to opposite poles during anaphase. The width of a 
nucleoplasmic bridge usually does not exceed 1/4* of the diameter of nuclei 
within the same cell. The nucleoplasmic bridges should have the same staining 
characteristic of the main nuclei. 
Nuclear Division Indices 
Nuclear Division Index (NDI) was also calculated according to the method 
of Eastmond and Tucker, (1989). More or less five hundred cells were scored to 
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determine the frequency of cells with one, two three or four nuclei. NDI was 
calculated employing the following formula, 
NDI = [N, + 2(N2) + 3(N3) + 4(N4)] / N* 
Where N1-N4 represents the number of cells with one to four nuclei and N* 
is the total number of viable cells scored. The NDI and proportion of binucleated 
cells are useful parameters for comparing the mitogenic response of lymphocytes 
and cytostatic effects of testing agents. 
A more accurate estimate of nuclear division status, cell division kinetics 
and cytotoxicity study can be obtained using the following equation which takes 
account of viable cells as well as necrotic and apoptotic cells 
NDCI = [Ap + No + Ni + 2(N2) + 3(N3) + 4(N4)1 / Nj 
Where N1-N4 represents the number of cells with one to four nuclei, Ap and 
Nc are count of apoptotic and necrotic cell respectively. Total number of viable 
and non-viable cells has been shown as NT-
Cells showing chromatin condensation with intact cytoplasmic and nuclear 
boundaries or cells exhibiting nuclear fragmentation into smaller nuclear bodies 
within an intact cytoplasm/cytoplasmic membrane are classified as apoptotic one 
while cells exhibiting a pale cytoplasm with numerous vacuoles and damaged 
cytoplasmic membrane with a fairly intact nucleus or cells exhibiting loss of 
cytoplasm and damaged/ irregular structure are classified as necrotic cells. 
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Statistical Analysis 
Standard Deviation (SD) and Standard Error (SE) were calculated using the 
following formulae-
Mean, I = TXIn 
Variance, a ' = "^  ^'^ 
11-1 
Standard Deviation, /-r- ='\J^ ^^-^ 
^ n -1 
Standard Error, og _ ^ 
.11 
Where, x = variables 
n - number of observations 
1 = mean of variables 
Sx = sum of individual variables 
Regression Analysis 
Dose response relationships for all the concentrations were determined by 
means of regression coefficients and analysis was carried out using SPSS for 
windows. 
Tests of Significance 
Student's t test was used for calculating the statistical significance in 
chromosomal aberration, sister chromatid exchange and micronucleus assay to 
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compare the effects of induced with the respective control. The following formula 
was used for this purpose, 
, ^ 1^ (control) - ^2 (treated) 
/ (SE of control)^ + (SE of treated )' 
The statistical significance was calculated from Fisher and Yates table at 
(ni + n2 - 2) degree of freedom at 0.01 and 0.001 level of significance. 
The 2x3 Chi-Square test (y^) for homogeneity test of variance was used to 
analyze the cell growth kinetics and nuclear division kinetics with their respective 
normal control. The level of significance was tested from standard statistical tables 
of Fisher and Yates, (1963). 
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RESULTS 
Selected antitumor drugs were evaluated for their genotoxic effects on 
human lymphocytes. Chromosomal aberration assay, cytochalasin-blocked 
micronucleus assay, sister chromatid exchange assay, nuclear division and cell 
cycle kinetic studies were carried out for the purpose. The student's t-test was 
applied for the chromosomal aberrations, micronucleus and sister chromatid 
exchange assay. The 2 x 3 chi-square test was used for nuclear division and cell 
growth kinetic analysis. The level of significance was compared at p < 0.01 and p 
< 0.001 for all of the parameters. 
CHROMOSOMAL ABERRATION ASSAY 
Chromosomal aberration assay was performed for the study of different 
types of aberrations induced by the drugs viz. gaps, breaks, exchanges, dicentrics 
and rings. About hundred metaphases were studied per concentration for each 
drug. The student's t-test was employed to compare aberration frequency with 
normal controls. Gaps were excluded from the significance level studies. The level 
of significance was compared at p<0.01 and p<0.001 for all parameters. The 
cultures treated with Cyclophosphamide showed a significant increase in 
chromosomal aberrations. 
I. Anthracyclines: 
/. Idarubicin 
The results of chromosomal aberration analysis after Idarubicin exposure 
are present in table 1 -3 for 24 hours, 48 hours and 72 hours durations respectively. 
Graph illustrating dose and time dependent increase after Idarubicin treatment is 
presented in figure 1(A). Increase in chromosomal aberration frequency showed a 
significant linear relationship with drug concentration (r = 0.985, 0.936, and 0.963 
for 24, 48 and 72 hours respectively at p < 0.01, figure l(Bl-3)). For exposure of 
24 hour duration, drug concentrations of 0.1 |ag/ml and 0.5 |xg/ml were found to 
induce chromosomal aberrations, significant at p < 0.01, while aberrations induced 
by 1.0 )ag/ml and 2.0 ^g/ml of drug concentration were significant at p < 0.001. 
Only two maximum tested concentrations i. e. 1.0 |ig/ml and 2.0 |iig/ml were found 
to be significant at p < 0.001 for 48 hour exposure. After 72 hr treatment, all 
values were observed to be significantly different from control value. Initial 
concentrations of 0.001, 0.01 and 0.1|ug/ml showed an increase in aberrations, 
which were significant at p < 0.01 and 0.5, 1.0 and 2.0 |ig/ml at p < 0.001. 
Among types of aberrations induced by Idarubicin, chromatid breaks (24%) 
and dicentrics (22%) shared the highest frequency, followed by chromosome 
breaks, exchanges and gaps and rings were the least observed aberrations. Percent 
values have been presented in the form of pie diagram in figure 3. 
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Figure 1: Chromosomal aberrations after Idarubicin treatments in-vitro 
(A): Dose and time dependent increase, Symbol (§) denotes significance at 
p < 0.001 and (*) at p < 0.01 
(Bl-3): Regression showing the efTects of concentration for 24, 48 and 72 hr 
respectively. 
2. Doxorubicin: 
The results of chromosomal aberration analysis after Doxorubicin exposure 
have been shown in table 4-6 for 24 hours, 48 hours and 72 hours exposure 
respectively. Figure 2(A) shows graphical presentation of time and dose dependent 
increase in chromosomal aberration count. There was observed a significant linear 
correlation of chromosomal aberration frequency with drug concentration (r = 
0.873 p<0.05, r = 0.987 p<0.01, r = 0.883 p<0.05 for 24, 48 and 72 hours 
respectively, Figure 2(Bl-3)). At 1.0 and 2.0 ^g/ml of concentrations, values of 
chromosomal aberrations were found significant at p<0.001 for all three exposure 
durations. For 24 hour exposure of duration, two of the lower drug concentrations 
were not found to be significant when compared with normal control, while 
concentrations of O.l^g/ml and 0.5ng/ml were found to induce chromosomal 
aberrations significant at p < 0.001 and p < 0.01. Three lowest doses of exposure 
did not induce significant increase in chromosomal aberration frequency at 48 hr 
duration. After 72 hr treatment, concentrations of 0.01 and 0.5 |ig/ml also induced 
increase in chromosomal aberrations significantly (p<0.001). Frequency of 
different types of aberrations has been presented as pie diagram in figure 3. Gaps 
were observed to be the most frequent while rings being the least. 
Figure 7(A) presents a comparative view of the frequency of chromosomal 
aberration induced by two drugs, Idarubicin and Doxorubicin, at minimum and 
maximum concentrations for all three exposure durations. 
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Figure 2: Chromosomal aberrations after Doxorubicin treatments in-vitro 
(A): Dose and time dependent increase, Symbol (§) denotes signiflcance at 
p < 0.001 and (*) at p < 0.01 
(Bl-3): Regression showing the effects of concentration for 24, 48 and 72 hr 
respectively. 
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Figure 3: Pie diagram sliowing percent contributions of each type of 
chromosomal aberrations induced by Idarubicin and 
Doxorubicin 
II. Alkylating antitumor drugs 
/. Cisplatin 
Frequencies of chromosomal aberration after Cisplatin exposure have been 
summarized in table 7-9 for 24 hours, 48 hours and 72 hours of exposure 
respectively. A comparative account of increase in chromosomal aberration 
frequency has been shown graphically in figure 4(A). A significant positive 
correlation was observed with the concentration increase and the chromosomal 
aberration count (r = 0.994 p<0.01, r = 0.979 p<0.01 and r = 0.764 p<0.05 for 24, 
48 and 72 hours respectively, figure 4(Bl-3)). Chromosomal aberration 
frequencies at 0.001, 0.01 and 0.1 |j.g/ml concentration of the drug was not found 
significantly effective for 24 hr and 48 hr duration of exposure. Increase in 
frequency was significant at p < 0.01 for 0.5 |ig/ml and at p < 0.001 for 1.0 and 2.0 
)ig/ml for both the exposure durations. For 72 hr of incubation time, initial two 
concentrations did not show considerable increase in aberrations. A significant 
increase was found for higher concentrations at p < 0.001. Comparison of different 
types of aberrations induced by the drug has also been made and is presented in 
the form of pie diagram in figure 6. 
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Figure 4: Chromosomal aberrations after Cisplatin treatments in-vitro 
(A): Dose and time dependent increase, Symbol (§) denotes significance at 
p < 0.001 and (*) at p < 0.01 
(Bl-3): Regression showing the effects of concentration for 24, 48 and 72 hr 
respectively. 
2. Dacarbazine 
The effects of the drug Dacarbazine on the frequency of chromosomal 
aberrations in human lymphocytes have been summarized in tables 10-12 for 24 
hours, 48 hours and 72 hours exposure respectively. Figure 5(A) graphically 
summarizes dose and time dependent influence of Dacarbazine on chromosomal 
aberration frequency. A higher degree of correlation was observed in 
chromosomal aberration frequency with concentration (r = 0.981, 0.972 and Q.955 
for 24, 48 and 72 hours respectively significant at p<0.01, figure 5(Bl-3)). At 
lower drug concentrations (0.001 and 0.01 |ig/ml), no significant difference was 
observed for all three culture timings. At 24 hr and 48 hr exposure durations, 
aberration count was significantly high for 0.5, 1.0 and 2.0 |ig/ml of concentration. 
After 72 hr drug treatment, 0.1 ^g/ml of concentration was found to increase 
chromosomal aberration frequency significantly at p < 0.01 and for 0.5, 1.0 and 
2.0 (ig/ml being significant at p < 0.001 levels. 
Percent wise contribution of each type of aberration has been figured in the 
pie diagram (Figure 6). Gaps showed highest contribution, followed by rings and 
the least by dicentrics. 
A comparison of minimum and maximum doses of both alkylating agents 
has been made graphically for all three durations and is presented in figure 7(B). 
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Figure 5: Chromosomal aberrations after Dacarbazine treatments in-vitro 
(A): Dose and time dependent increase, Symbol (§) denotes significance at 
p < 0.001 and (*) at p < 0.01 
(Bl-3): Regression showing the effects of concentration for 24, 48 and 72 hr 
respectively. 
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SISTER CHROMATID EXCHANGE ASSAY 
Sister Chromatid Exchange Assay was exploited for the study of DNA 
exchanges between sister chromatids and cell cycle kinetics. Replication indices 
were calculated for each exposure concentration according to the formula. The 
student's t-test was applied in order to compare the sister chromatid exchange 
frequency data from those of the normal control. The 2 x 3 chi-square test was 
used for the analysis of replication indices. The level of significance was 
compared at p < 0.01 and p < 0.001 for all of the parameters. 
A. Sister Chromatid Exchange Studies 
I. Anthracyclines 
1. Idarubicin 
Results of sister chromatid exchange assay after Idarubicin treatments are 
present in table 13. The mean frequencies of sister chromatid exchanges was 
found to be increased with rising concentration of drug (r = 0.984 p<0.01, figure 
8(B1)). At 0.001 ^g/ml concentration, the mean sister chromatid exchange 
frequencies were not found to increase significantly as compared to the value of 
the normal control. The drug significantly induced increase (p<0.001) in the mean 
sister chromatid exchange frequency at 0.01, 0.1 and 0.5 ng/ml of concentration. 
Results could not be obtained at 1.0 ng/ml of concentration. 
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2. Doxorubicin 
The data showing the mean sister chromatid exchange frequency induced 
by Doxorubicin in cultured human lymphocytes is summarized in table 14. A dose 
dependent increase was observed in mean frequencies of SCE (r = 0.992 p<0.01, 
figure 8(B2)). At 0.001 ^g/ml, difference in the mean values was found to be 
statistically significant from control at p<0.01. All the higher doses of 0.01, 0.1, 
0.5 and 1.0 ng/ml induced high score of sister chromatid exchange frequencies 
which were found to be significantly different at p<0.001. 
A comparison of exchange frequencies induced by Idarubicin and Doxorubicin 
has been gr^hically presented in figure 8(A). 
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Table 13: Sister Chromatid Exchange frequency induced by 
Idarubicin in human lymphocytes in-vitro 
Drug 
Concentration 
Idarubicin 
O.OOlng/ml 
O.Ol^ g/ml 
0.1 |ag/ml 
0.5 ^g/ml 
1.0 ^g/ml 
Controls 
Positive 
Negative 
Number of 
Metaphases 
observed 
50 
50 
50 
32 
-
50 
50 
Total 
SCE count 
185 
290 
513 
679 
-
682 
179 
SCEs per cell 
±SE 
3.7 ±0.25 
5.8 ±0.38** 
10.3 ±0.73** 
21.2±2.1** 
-
13.64±1.15** 
3.58 ±0.31 
CP = Cyclophosphamide SE = Standard error 
* Significant at P<0.01. ** Significant at P<0.00 
Table 14: Sister Chromatid Exchange frequency induced by 
Doxorubicin in human lymphocytes in-vitro 
jj Number of y 4 i 
^ ^^^ .. Metaphases „^T-" ^ . SCEs per cell ± SE Concentration . *^  . SCE count *^  
observed 
Doxorubicin 
O.OOl^ g/ml 
O-Ol^ g/ml 
0.1 ng/ml 
0.5 ng/ml 
l.Ong/ml 
Controls 
Positive 
Negative 
50 
50 
39 
42 
12 
50 
50 
230 
340 
449 
827 
438 
682 
165 
4.6 ±0.31* 
6.8 ±0.47** 
11.5 ±0.89** 
19.7 ±1.27** 
36.5 ±1.83** 
13.6±1.15* 
3.3 ± 0.29 
CP = Cyclophosphamide SE = Standard error 
* Significant at P<0.01. ** Significant at P<0.001 
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Figure 8 : Sister chromatid exchange (SCE) frequency after anthracycline treatments 
(A) : Comparison of SCE frequency induced by Idarubicin and Doxorubicin, Symbol 
(§) denotes significance at p < 0.001 and (*) at p < 0.01 
(Bl-2) : Regression showing the effects of concentration on SCE frequency for 
Idarubicin and Doxorubicin respectively. 
II. Alkylating Agent 
/. Cisplatin 
The effect of Cisplatin on the induction of sister chromatid exchanges has 
been presented in table 15. Mean frequency of sister chromatid exchanges was 
found to increase with the rise in concentration (r = 0.994 p<0.01, figure ((Bl)). 
No significant increase was observed at O.OOl^ g/ml of concentration. Value of 
mean frequency induced by 0.01 ng/ml of the drug was significant at p<0.01. 
Higher concentrations showed higher frequencies of sister chromatid exchanges 
which were significant at p<0.001. 
2. Dacarbazine 
The results of sister chromatid exchange analysis after Dacarbazine 
treatment are shown in table no 16. A continuous and significant increase in mean 
SCE frequency was found with the increase in drug concentration (r = 0.994 
p<0.01, figure 9(B2)). Minimal tested concentration did not show any noticeable 
increase whereas the increase was significant at p<0.01 for 0.01 |ig/ml of drug 
concentration. A considerable increase in mean SCE frequency after treatment 
with 0.1, 0.5 and 1.0 )ig/ml concentrations was observed, which again was 
significant at p<0.001. 
Figure 9(A) presents a comparative account of sister chromatid exchange 
frequency induced by both alkylating agents. 
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Table 15: Sister Chromatid Exchange frequency induced by 
Cisplatin in human lymphocytes in-vitro 
^ Number of ^ 
^ ^ ^. Metaphases ^^J^ ^ ^ SCEs per cell ± SE Concentration . , SCE count ^ 
observed 
Cisplatin 
O.OOlng/ml 
O.Ol^ g/ml 
0.1 ^g/ml 
0.5 ng/ml 
LO^g/ml 
Controls 
Positive 
Negative 
50 
50 
50 
42 
23 
50 
50 
205 
310 
490 
769 
812 
682 
190 
4.1±0.21 
6.2±0.63* 
9.8±0.68** 
18.3±0.93** 
35.3±1.82** 
13.6±1.15** 
3.8±0.48 
CP = Cyclophosphamide SE = Standard error 
* Significant at P<0.01. ** Significant at P<0.001 
Table 16: Sister Chromatid Exchange frequency induced by 
Dacarbazine in human lymphocytes in-vitro 
J. Number of „ . 
^ ^^^ ^. Metaphases „ „„^ ^ ^ SCEs per cell ± SE Concentration , *^  , SCE count 
observed 
Dacarbazine 
O.OOl^ ig/ml 
0.01^g/ml 
0.1 ^g/ml 
0.5 ^g/ml 
l.O^g/ml 
Controls 
Positive 
Negative 
50 
50 
50 
41 
27 
50 
50 
170 
272 
475 
734 
894 
682 
185 
3.4 ± 0.22 
5.4 ±0.40* 
9.5 ±0.83** 
17.9±1.21** 
33.1 ±2.61** 
13.64± 1.15** 
3.7 ±0.35 
CP=Cyclophosphamide SE = Standard error 
* Significant at P<0.01. ** Significant at P<0.001 
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Figure 9 : Sister chromatid exchange (SCE) frequency after alkylating drug treatments 
(A) : Comparison of SCE frequency induced by Cisplatin and Dacarbazine, Symbol 
(§) denotes significance at p < 0.001 and (*) at p < 0.01 
(Bl-2) : Regression showing the effects of concentration on SCE frequency for Cisplatin 
and Dacarbazine respectively. 
B. Cell Cycle Kinetics Assay 
I. Anthracyclines 
1. Idarubicin 
Results of cell cycle kinetic studies after Idarubicin treatment are presented 
in table 17. Percentage of cells, in 1 ^ \ 2"'^  and 3"* mitotic divisions were noted and 
their replication index was calculated. A significant decrease was observed in 
replication indices corresponding to given concentrations (r = -0.922 p<0.05, 
figure lO(Bl)). Idarubicin did not affect the proliferation of lymphocytes at 0.001 
|ig/ml of concentration. At 0.01 |ig/ml, the replication index was 1.62, difference 
from normal control being significant at p<0.01. Further decreases in replication 
indices were found to be significantly different at p<0.001. Data at 1.0 |J.g/ml of 
concentration could not be obtained probably due to higher toxicity. 
2. Doxorubicin 
Analysis of cell growth kinetics after Doxorubicin treatment has been 
reported in table 18. A continuous dose-dependent decrease was observed in 
replication indices (r = -0.964 p<0.01, figure 10(B2)). Decline in replication 
indices was not significant at 0.001 and 0.01|j,g/ml of doxorubicin concentration. 
At 0.1 )ig/ml, replication index was found to be significantly different at p<0.01, 
when compared to normal control. More decrease in replication indices were 
observed at 0.5 and 1.0 ^ig/ml, which was significant at p<0.001. Figure 10(A) 
graphically shows comparison of the decline of replication indices induced by two 
anthracyclines. 
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Figure 10 : Replication indices (RI) after anthracycline treatments in-vitro 
(A) : Comparison of the effect on replication indices caused by Idarubicin and 
Doxorubicin 
(Bl-2) : Regression showing the effects of concentration on RI for Idarubicin and 
Doxorubicin respectively. 
II. Alkylating Agent 
1. Cisplatin 
Data for the analysis of cell cycle kinetics after cisplatin exposure has been 
presented in table 19. The cells in 1^ ', 2"** and 3'^ '' mitotic divisions were scored and 
replication index was calculated. A constant decline in replication indices was 
experienced (r = -0.971 p<0.01, figure 11(B1)). The decrease was not considerable 
for initial two concentrations, though later on, for higher exposures, decline was 
found to be quite significant at p<0.001. 
2. Dacarbazine 
Analysis of cell growth kinetics after Dacarbazine treatment has been 
summarized in table 20. Percentage of cells, in 1^ *, 2"'^  and 3'^ '' mitotic divisions, 
was observed and replication index was calculated. Replication indices were found 
to decrease with increase in drug concentration (r = -0.993 p<0.01 figure 11(B2)). 
Dacarbazine did not induce any significant change at 0.001, 0.01 and 0.1 |Lig/ml of 
experimental concentration. A considerably significant (p<0.001) decrease in 
replication index was observed after treatment with 0.5 and I.O x^g/ml of 
concentrations. Figure 11(A) gives comparison of decline in the replication 
indices induced by Cisplatin and Dacarbazine. 
77 
u 
« 
go 
• M 
o 
a, 
s 
S 
s 
en 
ON 
1 — ( 
H 
c o 
S 
U 
O JS 
4> 
s 
;. e 
e 
o 
U 
* # * 
00 00 * * * 
t ^ \ 0 >r) 00 (N 
^ ' _ ; "Ti r<-) ^ -
vo 00 
2 <- vo ;:: 
00 
iri "^  V-) 
ON 
^ 
i n 
m 
C7\ 
^ 
_ 
^ 
m 
(N 
IT) 
(N 
rn 
a\ r<-i 00 ^ '^ VO 
O 
o6 00 00 — 
0 0 
o 
o 
o o o o 
o o ON 
o o o o 
.= - i 
^ e £ E 
5P ~£D "0!) ~Sb »5 
^ =L 
S o 
^ i O 
>n O fc; 
d — c 
o U 
Cu 
O 
(U 
> 
' • * - • 
'K 
o Cu 
(U 
> 
'•S 
cS 00 
u 
2 
C5 
O 
> 
O T3 
i §• 
it, " 
S u 
c o 
> 
'•B 
<*-
o j j 
o — 
o o 
-a d 
o a. 
.E c 
c o 
> 
'•B 
u-
o 
— 
u o 
*i V 
g a. 
c ^ 
if 
o 
XI 
a 
o 
s 
s 
O (» h< O 
OD a 
• • 
o 
H 
o 
« -a 
••iJS 
s 
CM 9i 
© j a 
0^  
c 
'••5 
a 
o 
U 
* * 
m —< 00 * • 
C50 00 r^ i n 00 
^ ^ ^ IT) rn 
OS o 
(N 
22 d 
ON 
>n 
O 
O 
O O 
O O 
00 
m 
00 
00 
ON' 
SO 
f^ 
OS 
en 
0 
"* 
so 
0 
>n 
ON' 
in 
so 
r~^  
so 
(N 
ON 00 
4^ 
' N 
X) 
« 
Q 
A 00 
o — 
o o 
d d 
00 
I t 
£ E 
m o 
d — 
• so 
so 00 
^ !:: 
so 
en 
00 — 
in m 
o o o o 
^ •- "-5 
I I o 
G3 
z 
B O 
> 
'•B («-. 
o 
u E 
•a rt C f 
^° 
(U O 
U >^  
u "^ 
c 
o 
o 
_u 
o — 
>. o 
O o 
c V 
° a. 
"53 S 
00 
> 
1 * . 
o 
u 
o o 
"^ IS 
U ^ 
II ^ 
0.001 ng/ml 0.01 ^g/ml 0.1 ng/ml 0.5 ng/ml 
Drug Concentration 
.0 ng/ml 
l,8i 
1.6 
1.4 
1.2 
1.0 
-
Y= 1.69 +0.59 X 
V. B l 
^ ^ ^ . . ^ ^ ^ 
• -• 
1 .1 .3 .5 .7 .9 1.1 
Drug Concentration (|Jg/ml) 
i.9i 
1.7 
1.5 
1.3 
-. 
] 
Y = 
1 .1 
1.82 +0.46 X 
B2 
• "^ ^^ ^ 
.3 .5 .7 .9 1.1 
3rug Concentration (|ig/nil) 
Figure 11 : Replication indices (RI) after alkylating drug treatments in vitro 
(A) : Comparison of the effect on replication indices caused by Cisplatin and 
Dacarbazine 
(61-2) : Regression showing the effects of concentration on RI for Cisplatin and 
Dacarbazine respectively. 
CYTOCHALASIN BLOCKED MICRONUCLEUS ASSAY 
Cytochalasin blocked micronucleus assay was utilized for the study of 
multiple parameters viz. micronucleus, nucleoplasmic bridges, nuclear division 
index and nuclear division cytotoxicity index studies. The student's t-test was 
applied for the micronucleus studies to be compared with data on normal control. 
The 2 x 3 chi-square test was used for the analysis of nuclear division and nuclear 
division cytotoxicity indices. The level of significance was compared at p < 0.01 
and p < 0.001 for all of the parameters. 
A. Micronucleus studies 
I. Anthracyclines 
/. Idarubicin 
Results of cytochalasin blocked micronucleus assay after Idarubicin 
treatment has been summarized in table no 21. At 0.001 |ig/ml, increase in percent 
micronucleated cells was found to be significant (p<0.01). For higher drug 
concentrations viz 0.01, 0.1, 0.5 and 1.0 fig/ml, the increase was still higher at 
significance level of p<0.001. Cells were also observed with more than one 
micronucleus that is why a difference in total count of micronuclei and 
micronucleated cells was observed. Increase in micronucleus frequency was dose-
dependent (r = 0.955 p<0.01, figure 12(B1). 
2. Doxorubicin 
Table 22 summarizes the effect of Doxorubicin on the induction of 
micronucleus frequency in human lymphocytes. There was observed a significant 
increase (p < 0.01) in percent micronucleated cell frequency at 0.001 |ig/ml. 
Increase for higher drug concentrations was significant at p < 0.001. An overall 
dose-dependent increase was observed in percent micronucleated cell count (r = 
0.933 p<0.05, figure 12(B2)). Figure 12 (A) illustrates graphical comparison of 
increase in percent micronucleated cells of the two anthracyclines. 
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Figure 12 : Micronucleus frequency after anthracycline treatments in-vitro 
(A) : Graphical comparison of Vo micronucleated cells induced by Idarubicin 
and Doxorubicin, symbol (§) denotes significance at p < 0.001 and (*) at p 
<0.01 
( B l - 2 ) : Regression showing the effects of concentration on micronucleus 
frequency for Idarubicin and Doxorubicin respectively. 
II. Alkylating Agent 
1. Cisplatin 
The effect of Cisplatin on micronucleus frequency has been summarized in 
table 23. A significant dose-dependent increase was observed in percent 
micronucleated cells (r = 0.993 p<0.01, figure 13(B1)). Drug concentration of 
0.001 |ig/ml did not induce any significant difference in micronucleus frequency 
when compared to normal control value. An increase, significant at p < 0.01, was 
observed in cultures treated at 0.01 |ig/ml of cisplatin concentration. All the higher 
drug concentrations significantly induced increased frequency of micronucleated 
cells at p< 0.001. 
2. Dacarbazine 
The results obtained from cytochalasin blocked micronucleus assay after 
Dacarbazine treatment have been presented in table 24. A significantly positive 
dose-dependent correlation was observed in percent micronucleated cells (r = 
0.996 p<0.01, figure 13(B2)). Increase in micronucleated cells was insignificant 
for the minimum concentration but was significant (p < 0.01) at 0.01|ig/ml. 
Dacarbazine concentration of 0.1, 0.5 and 1.0 i^g/ml showed important increase in 
micronucleated cell count which was found to be significant at p < 0.001. 
Figure 13(A) illustrates graphical comparison of increase in percent 
micronucleated cells of the Cisplatin and Dacarbazine. 
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Figure 13 : Micronucleus frequency after alkylating drug treatments in-vitro 
(A) : Graphical comparison of % micronucleated cells induced by Cisplatin 
and Dacarbazine, symbol (§) denotes significance at p < 0.001 and (*) at 
p < 0.01 
(Bl-2) : Regression showing the effects of concentration on micronucleus 
frequency for Cisplatin and Dacarbazine respectively. 
B. Nuclear Division Index analysis 
1. Anthracyclines 
/ . Idarubicin 
Results of analysis of nuclear division (NDI) and cytotoxicity indices (NDCI), 
after Idarubicin treatment, have been summarized in table 25 and 26 respectively. Viable 
(single, double, three and four nucleated) cells and non viable (apoptotic and necrotic) 
cells were observed and nuclear division indices were calculated according to respective 
formula. There was observed a dose dependent decline both in NDI (r = -0.902 p<0.05, 
figure 14(B1)) and NDCI (r = -0.898 p<0.05, figure 15(B1)) as well as significant 
decrease in proliferating capacity of lymphocyte at of all the experimental concentrations. 
2. Doxorubicin 
Data for the analysis of Doxorubicin's effect on nuclear division and cytotoxicity 
indices has been presented in table 27 and 28 respectively. Cells with single, double, 
triple and four nuclei were scored along with apoptotic and necrotic cells and nuclear 
division indices were calculated for each concentration. A significant but negative 
correlation was observed in nuclear division indices (r = -0.919 p<0.05. figure 14(B2)) 
and cytotoxicity indices (r = -0.903 p<0.05, figure 15(82)) corresponding to given 
concentrations. No considerable decrease was observed at lower exposures of 
doxorubicin. However, decline in nuclear division index was prominently significant 
(p<0.001) at higher concentrations. A graphical comparison of nuclear division and 
cytotoxicity indices after treatment with two anthracyclines has been presented in figures 
14(A) and 15(A) respectively. 
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Figure 14: Nuclear division index (NDI) after anthracycline treatments in-vitro 
(A) : Comparison of the effect on nuclear division indices caused by Idarubicin 
and Doxorubicin 
(Bl-2) : Regression showing the effects of concentration on NDI for Idarubicin 
and Doxorubicin respectively. 
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Figure 15 : Nuclear division cytotoxicity index (NDCI) after anthracycline treatments 
(A) : Comparison of the effect on nuclear division cytotoxicity indices caused by 
Idarubicin and Doxorubicin 
(Bl-2) : Regression showing the effects of concentration on NDCI for Idarubicin 
and Doxorubicin respectively. 
II. Alkylating Agent 
1. Cisplatin 
Table 29 and 30 summarize observations for the analysis of nuclear 
division and cytotoxicity indices after Cisplatin exposure on human lymphocytes. 
Cells with single, double, triple and four nuclei as well as those undergoing 
necrosis and apoptosis were scored and indices were calculated as per the given 
formula. A continuous dose-dependent decline was observed in NDI (r = -0.920 
p<0.05, figure 16(B1)) and NDCI (r - -0.918 p<0.05, figure 17(B1)). Two initial 
concentrations did not induce considerable decrease in indices, while at 0.1, 0.5 
and 1.0 |ig/ml the decrease was found to be significant at p<0.001, compared to 
normal control values. 
2. Dacarbazine 
The effect of Dacarbazine treatment on nuclear division and cytotoxicity 
indices in cultured human lymphocytes has been shown in table 31 and 32. Viable 
(single, double, three and four nucleated) cells and non viable (apoptotic and 
necrotic) cells were observed and nuclear division indices were calculated 
according to the respective formula. A significant and important dose-dependent 
decrease was observed for the experimental concentrations in NDI (r = -0.852 
p<0.05, figure 16(B2)) and NDCI (r = -0.855 p<0.05, figure 17(B2)). 
Figures 16(A) and 17(A) show comparison of the decline of nuclear 
division and cytotoxicity indices as affected by Cisplatin and Dacarbazine. 
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Figure 16 : Nuclear Division Index (NDI) alkylating drug treatments in-vitro 
(A) : Comparison of the eflect on nuclear division indices caused by Cisplatin 
and Dacarbazine 
(Bl-2) : Regression showing the effects of concentration on NDI for Cisplatin and 
Dacarbazine respectively. 
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Figure 17 : Nuclear Division Cytotoxicity Index (NDCI) after alkylating drug treatments 
(A) : Comparison of the effect on nuclear division cytotoxicity indices caused by 
Cisplatin and Dacarbazine 
(Bl-2) : Regression showing the effects of concentration on NDCI for Cisplatin and 
Dacarbazine respectively. 
DISCUSSION 
In the present work in vitro cytogenetic studies on the effects of some 
selected anticancer drugs have been done. The advantages, disadvantages, 
objectives and limitations of used test systems, the parameter assayed and 
cytogenetic and clinical effects of the drugs evaluated on these parameters are 
discussed below. 
GENERAL CONSIDERATION 
Genetic toxicological studies are usually performed through in vivo and/or 
in vitro screening. For human systems in vivo cytogenetic evaluation has its own 
shortcomings. These studies are possible only in particular cases where individuals 
have been exposed to the agents either as medical necessity or occupational 
regularity. The genotoxicity evaluations among patients on therapy are 
complicated. Patient may have faced exposure to different kinds of insults and to 
find out the effect of a particular type of exposure is not easy. Peripheral 
lymphocytes (from patients after treatment) are cultured by PHA stimulation and 
hence are not in the dividing cell stage at the time the chemicals exert their 
influence in vivo. Drugs, which manifest their detrimental effects in S phase, may 
not exhibit cytogenetic damage in lymphocyte cultures of exposed patients. 
These shortcomings of the in vivo evaluations can be overcome by in vitro 
treatment of peripheral blood lymphocytes in cultures. The experimental approach 
can be used and the effect of drugs/chemicals can be evaluated at a given range of 
concentrations. This also permits the evaluation of effects of different time 
exposures of the drug and the fate of lesions after consecutive cell divisions as 
well as the effect of the drug during the Gi and S phase of cell cycle. Selected 
drugs were studied for their in vitro toxic effects on human lymphocyte 
chromosomes employing peripheral blood lymphocyte culture for various assays. 
Chromosome Aberrations 
Assessment of chromosomal aberrations serves as a good indicator of the 
clastogenic effects of agents (Metcalfe and Sonstegard, 1986; Dhillon et al., 1995) 
and it is being done routinely in our laboratory (Azfer and Afzal, 1996; Ahmad et 
al., 2000; Siddique et al., 2005a; 2006). The aberrations can be classified into 
chromatid type aberrations which are induced in the latest So or G2 phase cell 
cycle and the chromosome type aberrations which are caused by damage to the 
chromosome materials in the G\ or early S phase. Achromatic lesions are non-
staining or very light staining regions of chromosomes present in one chromatid or 
both the sister chromatid at identical loci. Their frequency should not be included 
in totals for aberration per cell, since significance and relationship to other true 
aberration types is still not clear. The association between chromosome alterations 
and the development of tumors enhances their utility as a relevant end point in 
short term mutagenicity assays. 
Sister Chromatid Exchanges 
Sister chromatid exchanges (SCE) represent the interchange of DNA 
strands between sister chromatids at apparently homologous loci. The frequency 
of SCEs has been found to be greatly increased on exposure to mutagenic agents. 
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Therefore, SCEs are considered to be sensitive indicators of DNA damage (Wulf, 
1990; Tucker et al, 1993; Siddique and Afzal, 2004; 2005b). Scoring of 
replication indices is a sensitive method for detecting delay or stimulation in 
human lymphocyte cultures (Lazutka and Margolin, 1991). 
Cytochalasin Blocked Micronucleus Assay 
Micronuclei are expressed in dividing cells that either contain chromosome 
breaks lacking centromeres and/or whole chromosomes that are unable to travel to 
the spindle poles during mitosis. Because micronuclei are expressed in cells that 
have completed nuclear division, they are ideally scored in binucleated stage of 
cell cycle (Fenech, 2000; Fenech and Morley, 1985). Nucleoplasmic bridges 
between the nuclei are also observed which probably represent dicentric 
chromosomes in which the two centromeres are pulled to opposite poles and DNA 
in the resulting bridge is covered by nuclear membrane. These provide an 
additional and complementary measure of chromosome rearrangement, which can 
be scored together with micronucleus counts. The nuclear division indices are 
useful parameters for comparing the mitogenic response of lymphocytes and 
cytostatic effects of agents examined in the assay (Kirsch-Volders et al., 1991; 
Fenech, 1999). Nuclear division cytotoxicity assay additionally involve two 
morphological patterns, necrosis and apoptosis that characterize cell death 
(Wyllie, 1987). Necrosis results when a cell is traumatically damaged and 
apoptosis, the programmed cell death, is a controlled pathway that requires new 
protein synthesis. 
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CYTOGENETIC EFFECTS OF ANTICANCER DRUGS 
Anthracyclines 
The anthracycline antibiotics are extensively used in cancer chemotherapy. 
Doxorubicin, one of the primarily used anthracyclines, is regularly utilized for the 
treatment of breast cancer (Henderson and Canellos, 1980; Hiddemann et al., 
2005), while Idarubicin (4-demethoxy-daunorubicin) is a synthetic analog of 
daunorubicin, the first generation anthracycline antibiotic. It is recommended 
primarily for the treatment of acute myelogenous leukemia, acute lymphoblastic 
leukemia in children, chronic myelogenous leukemia, myeloblastic syndrome and 
breast cancer (Cersosimo, 1992; Seiter, 2005). 
Both of the anthracyclines induced significantly increased chromosomal 
abnormalities per cell as well as in the total number of abnormal cells when 
compared with the normal control in the present study (Khan et al, 2009). In case 
of Idarubicin, increase in the aberrations was found to be significant at almost all 
of the concentrations and exposure durations except for few lower dose 
concentrations. Chromatid breaks were observed in maximum percentage 
frequency followed by dicentrics. Lower exposure concentrations of doxorubicin 
did not induce high frequency of aberrations, though with increasing 
concentrations higher degree of significance was observed. Among abnormalities 
induced by Doxorubicin, chromosome breaks shared highest frequency followed 
by dicentrics and then chromatid breaks. Both the anthracyclines induced rings in 
least percentage. 
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Doxorubicin has earlier been reported to induce chromosomal aberrations 
in mammalian cells (Tavares et al, 1998) and other topoisomerase II inhibitors 
such as etoposide, adriamycin, mitoxantrone (Suzuki and Nakane, 1994) and 
epirubicin (El-Mahdy Sayed Othman, 2000) have also been shown to increase 
different types of structural chromosomal aberrations in Chinese hamster cell 
lines. It is known that the Idarubicin, topoisomerase II and DNA complexes give 
rise to double strand breaks that may consequently be expressed as chromosomal 
aberrations (Palitti, 1993), thus triggering cell death process (Binaschi et al, 
1997). Idarubicin has also been observed to induce DNA damage and have been 
capable of suppressing the expression of oncogenes-C myc in the MCF-7 breast 
tumor cell line (Gewirtz et al, 1998). A correlation between inhibitory effect of 
Idarubicin on cell growth and on DNA synthesis has been shown earlier (Gewirtz 
e? a/., 1998). 
Anthracyclines consist of an aglycone ring coupled with an amino-sugar 
and can produce a wide range of biological effects. The planar ring can intercalate 
between DNA base pairs and the amino-sugar moiety can interact with negatively 
charged phosphate groups in the DNA major groove (Kellogg et al., 1998; Zhang 
and Li, 2000). The intercalation can cause changes in the shape of DNA helix 
interfering with transcription and replication. Anthracyclines can undergo one 
electron reduction and thus form oxygen free radical intermediates. In the presence 
of oxygen and metals, this can be reduced to a semiquinone radical, which, in turn 
can be converted to a hydroxyl radical (Abraham et al, 1996; Faure et al, 1998). 
108 
Free radicals can induce membrane lipid peroxidation, DNA strand scission and 
direct oxidation of purines and pyrimidines, thiols and amines. 
One of the primary mechanisms, considered to mediate the antiproliferative 
and cytotoxic effects of anthracycline antibiotics, is the inhibition of relegation 
activity of the enzyme topoisomerase II, an enzyme which introduces double 
strand breaks in DNA (Schneider et al., 1990; Bridewell et al., 1997). 
Topoisomerases are cellular enzymes essential for the maintenance of chromatin 
structure, replication of DNA and mitosis/meiosis in eukaryotic cells and are used 
as a major target for cancer chemotherapeutic attacks. These enzymes function by 
sequential breakage and relegation of either one (Topoisomerase I) or both 
(Topoisomerase II) DNA strands and strand passing associated with such 
breakage, alters the linking number of DNA (Wang, 1996). Both Doxorubicin and 
Idarubicin are topoisomerase II directed agents (Burden and Osheroff, 1998; 
Willmore et al., 2002). Inhibitors of DNA topoisomerase II that act by trapping the 
"cleavable complex" give rise to DNA single strand and double strand breaks. 
Double strand breaks are considered the uhimate lesion leading to chromosomal 
aberrations. Consequently, treatments with topoisomerase II inhibitors, depending 
on the phase of the cell cycle in which they are performed, induce chromosome-
type aberrations viz. Go or Gj treatment or chromatid-type aberrations viz. S or G2 
treatment (Palitti et al., 1994). 
Interference with topoisomerase Il-dependent decatenation of chromatids 
leads to an increase in mitotic recombination (Gorbsky, 1994; Chen and Beck, 
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1995). Topoisomerase targeting drugs may induce both S-phase specific or cell 
cycle phase non specific effects (Wang et al., 2007). The topoisomerase II poison 
and not the topoisomerase I poison can induce the formation of quadra-radial 
chromosomes apparently formed by reciprocal exchange between different 
chromosomes (Charron and Hancock, 1990). Recombinational events can lead to 
DNA deletions varying from one base up to more than one megabase, as well as to 
a variety of other events, including gene amplification (Di Leonardo et al., 1993). 
In the current experimental results we have reported induction of significant 
increase in the mean sister chromatid exchange frequency by both the 
anthracyclines at higher concentrations; whereas a significant decrease was 
observed in replication indices corresponding to all of the concentrations of both 
the drugs. For Doxorubicin, however, decline in replication indices was not 
significant at lower concentrations. Our results are in line with previous studies 
which have reported induction of sister chromatid exchanges by topoisomerase 
inhibitors namely amascrine, camptothecin, etoposide and nalidixic acid (Ribas et 
al., 1996). A number of previous studies support the hypothesis that 
topoisomerases stimulate S-phase-specific chromatid exchanges (Dillehay et al., 
1987; Ribas et al., 1996). Sister chromatid exchange frequencies and reduction of 
mitotic index has also been reported to be induced by topoisomerase II inhibitor 
'etoposide' in lymphoblastoid cell line (Fantini et al., 1998). Reports are also 
available of increased frequency of sister chromatid exchanges in peripheral 
lymphocytes of cancer patients receiving chemotherapy with adriamycin 
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(Musilova et al, 1979), nitrosourea (Lambert et al., 1978) and mitomycin 
(Ohtsuru et al., 1980). Inhibition of topoisomerase II function after replication 
may produce unfavorable DNA topology, leading to both homologous and non-
homologous recombination. In this regard, it is noteworthy that sister chromatid 
exchanges are induced by both topoisomerase I and II and correlate with 
cytotoxicity (Cortes et al., 1993; Chen et al., 1996). 
In case of cytochalasin blocked micronucleus assay, both the drugs induced 
higher extent of micronucleus count and a dose dependent decline was observed in 
nuclear division kinetics. Total count of necrotic and apoptotic cells was found to 
increase with concentration which influenced a dose-dependent decline in nuclear 
division cytotoxicity indices. Idarubicin has been previously reported to increase 
the frequency of micronuclei in human T lymphoblastoid CEM cell line (Stopper 
et al., 1999) and interferes with cell growth and induces cell death by inhibiting 
the activity of the enzyme topoisomerase II, which infact, results in the induction 
of DNA strand breaks (Zwelling et al., 1993). Morphological features of apoptosis 
in cells increasing with drug doses have been observed earlier and basal values of 
apoptosis have been found to be about 5-6% (Tompa et al., 2000; Gonzalez-Cid et 
al., 2002). Idarubicin has been reported to induce mean spontaneous apoptotic 
fractions measured by flow cytometry to 6.65±0.89% in lymphocytes from healthy 
subjects (Tompa et al., 2000). Apoptosis was induced independently of the cell 
cycle phase after treatment by high doses, whereas after relatively low doses, a 
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cell cycle arrest in G2 phase was observed (Vial et al., 1997; Marekova et ai, 
2000). 
Amascrine, another anthracycline, has earlier been reported to induce 
megabase deletion in hamster human hybrid cell lines (Shibuya et al., 1994). 
Gromova et al. (1995) identified a pattern of topoisomerase II cleavage sites with 
a spacing of 50-200 kb and these represent binding sites at the bases of chromatid 
loops. Idarubicin has been shown to induce a significant increase in the tail 
moment of the comets of human lymphocytes (Felix, 1998; Josting et al., 2003). 
The increase in tail moment can be due to direct induction of strand breaks and/or 
generation of such modifications in DNA which can be transformed into strand 
breaks (Hande, 1998; Termini, 2000). 
There is now increasing evidence of secondary cancers in patients treated 
with such agents. Etoposide and teniposide were found to induce secondary acute 
myeloid leukemia (AML), with a short latency of onset of 2-3 years (Hawkins et 
al., 1992; Sandoval et al., 1993) and the resulting cells were having translocations. 
Such translocations have also been noted in de novo childhood leukemias (Cimino 
et al., 1993; Ross et al., 1994). Doxorubicin too has been found to induce 
secondary leukemia with chromosomal translocations similar to that observed in 
de novo AML (Sandoval et al., 1993). Doxorubicin, mitoxantrone and etoposide 
also induce secondary acute promyelocytic leukemia with chromosomal 
translocation (Detourmignies et al., 1992). 
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Among the two anthracyclines tested for genotoxicity, Idarubiein was 
found to show comparatively higher degree of toxicity and damage to genetic 
material than Doxorubicin in almost every parameter of present research. 
Idarubiein (4-demethoxy-daunorubicin) is a synthetic analog of daunorubicin. 
Deletion of the group increases lipophilicity of Idarubiein compared with that of 
Doxorubicin and enhances its uptake into cells and may increase its binding to 
DNA which may be attributed as the possible cause of higher genotoxic outcome. 
It forms free radicals to a lesser extent than other anthracyclines which accounts 
for reduced cardiotoxicity (Platel et al., 1999). However, the extent of DNA 
damage produced by Idarubiein has been reported to be relatively lower in 
comparison with few other topoisomerases II inhibitors (Gewirtz et al., 1993; 
Bunch et al., 1994) and lack of correspondence between DNA strand breaks and 
toxicity of Idarubiein has been reported (Ferrazzi et al., 1991; Zwelling et al., 
1993). 
Alkylating Agents 
Among various types of drugs designed for use in cancer chemotherapy, 
many have the potential for alkylation. These chemicals alkylate DNA bases, 
thereby preventing the muhiplication of rapidly growing tumor cells. We have 
selected two routinely used chemotherapeutic drugs namely, Cisplatin and 
Dacarbazine. These two alkylating drugs can be differentiated according to their 
preferred sites of action and their ability to form interstrand crosslinks in DNA 
(Eisenbrand et al, 1994; Choi et al., 2002; Gwak et al, 2005). The Platinum drug 
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complexes are believed to have primary binding sites on N^ or O^ of the DNA 
Guanine. This interaction results in inter and intra-strand cross-linking, forming 
DNA adducts. Dacarbazine functions by 0^-substituted Guanine residues by 
producing O -methylguanine as the primary lesion for cell killing. This modified 
base further reacts with a cytosine residue of the opposite strand to yield an 
interstrand crosslink in the DNA. 
In the current experimental work both of the tested alkylating drugs, 
Cisplatin and Dacarbazine were found to induce considerable increase in 
chromosomal aberrations in-vitro. There was observed a dose dependent increase 
in chromosomal abnormalities per cell as well as in total number of abnormal cell 
counts when compared with normal control. Higher concentration of Cisplatin 
showed significant increase in chromosomal aberration frequency but lower 
concentrations of it did not show any significant effect at any time duration. In 
case of Cisplatin, multiple types of chromosomal aberrations were observed but 
dicentrics and exchanges showed the highest frequency. 
Cisplatin is clinically important antineoplastic agent with activity against a 
wide spectrum of tumors. Our study with the platinum drug is in line with earlier 
studies which have reported Cisplatin induced chromosomal aberrations and cell 
killing in Chinese hamster ovary cells (Krishnaswamy and Dewey, 1993). 
Platinum drug induced chromosomal damage has also been described in cultured 
mammalian cells (Meyne and Lockhart, 1978; Srb and Prochazkova, 1983; 
Shinkai et ai, 1988). About 40 % of total breaks have been observed in Chinese 
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hamster ovary cells at 10 ng/ml (Gonzalez Cid et al, 1995). But in V79 cell line, 
no significant increase in chromosomal aberrations was found at 2.5 |ig/ml 
(Pleskova et al., 1984). Adler and el-Tarras (1989) have reported the induction of 
chromosomal aberrations in-vivo both in somatic and germinal cells treated with 
cisplatin. 
Carboplatin is the second most widely used platinum drug across the world 
and has been found to induce SCE at statistically significant level in human 
lymphocytes (Shinkai et al, 1988). In an in vitro study, high dose of carboplatin, 
have been observed to induce 7-fold increase in SCE frequency compared with the 
control accompanied by an important delay in cell cycle progression (Gonzalez 
Cid et al, 1995). Carboplatin have been found to show a significant increase in 
SCE frequency in lymphocytes both in vitro and in vivo and delay in the cell cycle 
resulting in a reduction of the number of cells in second division and increase of 
the same in the first division. However, carboplatin induces a decrease in mitotic 
indices. This shows an important cytotoxic effect through prolonging the cell cycle 
as a cytostatic agent (Gonzalez Cid et al., 1995). 
The platinum antitumor agents are unique coordination complexes and 
Cisplatin is the parent compound of this class. It is a known fact that Cisplatin and 
other platinum containing compounds target cellular DNA, forming covalent 
adducts (Johnson et al, 1994). DNA adducts are covalent complexes formed 
between chemicals and DNA bases which constitute a critical early intermediate 
on the pathway of chemical carcinogenesis (Kyrtopoulos et al., 1997). The most 
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common adducts formed by Cisplatin are 1,2-intrastrand d(GpG) crosslinks, 1,2-
intrastrand d(ApG) crosslinks and minor 1,3-intrastrand d(GpNpG) crosslinks 
(Teuben et al., 1999; Burstyn et al., 2000) and enforces rotational setting of DNA 
in nucleosomes (Danford et al, 2005). The major adducts are DNA intrastrand 
crosslinks but the DNA interstrand crosslinks that represent less than 1% of the 
total platination (Coste et al., 1999) have often been implicated more as the most 
cytotoxic lesions. Reports have indicated that a positive response of patients to 
Cisplatin correlates with the number of 1,2-intrastrand crosslinks found in tissue 
samples (Van De Vaart et al, 2000). The GC rich DNA sequences are the main 
binding sites of Cisplatin. The long tandem repeats of 5'-TTAGGG-3' sequences in 
human telomeres are potential targets for Cisplatin action (Ishii et al., 2000; 
Arutyunyan et al., 2005). Studies have revealed that telomeres in Cisplatin treated 
Hela cells are markedly shortened and degraded (Ishibashi and Lippard, 1998). 
The mutagenic potential of the pt (II) has also been demonstrated in E. coli 
(Bumouf e/ al., 1987; Ohta et al., 2002) and cytogenetic investigations have been 
shown that Pt (II) produces chromosome aberrations in Chinese Hamster Cell lines 
and both in human lymphocytes and Bone Marrow cells of mice (Wiencke et al., 
1979). Genotoxic effect of Cisplatin on the chromosomes of murine Dalton's 
lymphoma cells in in-vivo bone marrow cells has also been reported (Prasad et al., 
1992; Khynriam and Prasad, 2003). Cisplatin has been found to be specific 
inducer of lethal mutations in female mice (Blommaert et al., 1995). 
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At higher concentrations, significant increase was observed in sister 
chromatid exchange and micronucleus frequency accompanied by considerable 
decline in replication and nuclear division indices. Sister chromatid exchanges and 
chromosomal aberrations are both cytological manifestation of damage to the 
chromosomal DNA. It is generally accepted that the N^ or O^ atoms of the guanine 
in DNA are the primary binding sites of platinum complexes (Laurent et al., 
1981). This reaction with the formation of closed ring chelate results in inter-
strand and intra-strand cross linking (Terheggen et al., 1991). These effects of 
platinum complexes on DNA point to a typical mode of action of alkylating agents 
(Kainae^a/., 1993). 
Induction of micronuclei and granular chromatin condensation in human 
skin fibroblasts has been observed after Cisplatin treatment (Jirsova and Mandys, 
1994). Our results of micronucleus assay are in accordance with previous study 
which reported increase in frequency (p<0.001) of micronuclei in B and T 
lymphocytes in carboplatin treated cultures (Slavutsky et al., 1995) and increase in 
the micronucleus frequency with corresponding dose response relationship was 
observed (Gonzalez Cid et al., 1995). Carboplatin has also been found to induce 
significantly high MN both in the foetal liver and the maternal bone marrow in 
mouse in vivo test systems (Vijayalaxmi and D'Souza, 2004). Cycoplatum, another 
platinum drug which is effective in the treatment of pleural mesothelioma and 
ovarian carcinoma has been reported as inducer of micronuclei and a considerable 
clastogenic agent (Nersesyan et al., 2006). We have reported about 10 percent 
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apoptosis in cultures treated with maximum tested dose of Cisplatin. Cells exposed 
to Cisplatin earlier have been shovm to exhibit double-stranded DNA cleavage, 
blebbing of the cell surface and cell shrinkage, all of which are consistent with 
apoptosis as the means of cell death (Barry et al., 1990). 
For Dacarbazine also, a higher degree of correlation was observed in 
chromosomal aberration frequency for all concentrations and durations but only 
higher concentrations of the drug showed high significant increase in aberrations. 
Gaps showed highest contribution, followed by rings and the least by dicentrics. 
Dacarbazine has earlier been found to induce chromosomal anomalies in the form 
of chromatid breaks and gaps proportional to the dose of drug treatment in in-vivo 
test, utilizing mouse bone marrow cells (Al-Hawary and Al-SalQh, 1989). Single 
strand breaks have been observed in lymphocytes from patients undergoing 
chemotherapy with Dacarbazine (Walles and Ringborg, 1991). Temozolomide, 
another drug, undergoes hydrolysis in the body to produce monomethyl 
triazenoimidazole carboxamide (MTIC) which is structurally related to 
Dacarbazine and is thought to act as an alkylating agent. It is active in anaplastic 
oligodendroglial tumors treated at first recurrence and has been found associated 
with lp/19q allelic loss which is an important predictive and prognostic factor 
(Brandes et al., 2006). 
Dacarbazine is an imidazole carboxamide derivative with structural 
similarity to certain purines and its primary mode of action appears to be 
alkylation of nucleic acids. The 0^-meG is one of the most critical events in the 
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mutagenic and carcinogenic effects of alkylating agents (Souliotis et al, 1996) and 
its role in the origin of chromosome damage has got experimental support as well 
(Bean et al., 1994). The pathway of Dacarbazine involves a-hydroxylation at one 
of its N-methyl residues and conversion to 5-(3-hydroxymethyl-3-
methyl)imidazole-4-carboximide, followed by cascade of steps yielding the 
ultimate alkylating agent, the methyl diazonium ion, which reacts with DNA, 
producing various DNA adducts, e.g. N -methyl guanine and O -methyl guanine 
(Psaroudi and Kyrtopoulos, 2000; Sanada et al, 2004). The N^-meG is the 
most abundant lesion present in DNA and RNA in different rat tissues after 
Dacarbazine treatment. Whereas, 0^-meG is the one which posses miscoding 
properties when not repaired before DNA replication and tends to provoke 
clastogenic effects (Kaina, 2004). Detectable levels of 06-meG were found in the 
patients treated with Dacarbazine in combination therapy (Souliotis et al., 1991). 
Procarbazine administration has been observed to induce mutations other than 
those which are characteristic of 06-meG miscoding in the liver and bone marrow 
of mice, which may be an indication of some other mechanism involved (Pletsa et 
al., 1997). 
There was observed a continuous and significantly higher dose-dependent 
increase in micronucleus frequency accompanied by important decline of nuclear 
division indices in Dacarbazine treated cultures. The frequency of CREST^ 
micronuclei was found significantly increased after therapy with Dacarbazine 
(Miele et al., 1998). DTIC induced micronuclei, in somatic and germinal ceils of 
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mice, indicate that an increased genetic risk may exist for male patients after 
chemotherapy with Dacarbazine (Adler et ai, 2002). Micronucleus frequency has 
also been observed to be increased during first half of cancer chemotherapy and its 
decline was observed thereafter (Padjas et al., 2005). 
Among Dacarbazine treated cultures dose dependent increase in sister 
chromatid exchange fi^equency was observed with significant increase at higher 
concentrations and only higher concentration showed decline in replication 
indices. Significantly elevated SCE frequencies were induced in patients receiving 
two cycles of MOPP regimen which shares procarbazine as a constituent (Sen et 
al., 1990). Dacarbazine has previously been reported to give positive results for 
induction of sister chromatid exchanges in Chinese hamster cells in vitro and was 
mutagenic to cultured rodent and bacterial cells (lARC Monographs, 1987). A 
triazeno analogue of dacarbazine, l-p-(3-methyltriazeno) benzoic acid potassium 
salt (MTBA) has been found to induce SCEs significantly in human lymphocytes 
(Vemole et al., 1988). The results of the studies based on the use of cells with 
different capacities to repair 0^-alkylguanine (0^-AlkGua) indicate a key role for 
this alkylation product in the induction of sister chromatid exchanges, 
chromosomal aberrations and micronuclei (Kaina, 2004). Boivin et al. (1995) has 
reported secondary cancers in patients with Hodgkin's disease, who were treated 
with chemotherapy. Dacarbazine is carcinogenic to experimental animals (Kumara 
et al., 2006) and its mutagenic effect has been reported in the mammalian cultured 
ceils (Bartoli-Klugmann et al., 1982). 
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Among alkylating drugs of experiment Cisplatin showed slightly higher 
genotoxic outcome in sister chromatid exchange and micronucleus assay than that 
of Dacarbazine but in chromosomal aberration assay towards maximum tested 
concentration and longer the duration Dacarbazine showed more potent effect. 
Dacarbazine showed low impact on cell cycle and nuclear division kinetics 
especially at lower concentrations. 
A number of follow up studies have been performed post chemotherapy to 
analyze probabilities of occurrence of secondary tumors (Brusamolino et al., 
2006). In one of such post chemotherapeutic studies of 111 ovarian cancer 
patients, the incidence of chromosome abnormalities and structural changes were 
observed to be much higher in the treated patients than in the control group. 
Abnormal karyotypes were observed in follow-up study of 25 % of patients after 6 
years of treatment (Islam et al., 1993). Carbonell and Colleagues (1996) pursued 
the frequency of sister chromatid exchanges and structural chromosomal 
aberrations in peripheral blood lymphocytes of the patients prior to treatment, just 
after and 3-7 weeks later, and observed a clear difference between basal level of 
cytogenetic aherations in cancer patients and healthy donors. 
Different drug regimens have been shown to produce different patterns of 
changes in sister chromatid exchange frequency. These may be related to their 
potential to induce secondary malignancies. Structural aberrations and 
micronucleus studies on peripheral lymphocytes have been confirmed as among 
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sensitive biomarker for biomonitoring of acute cytogenetic effects induced by 
antineoplastic drugs (Kopjar et al., 2002). 
CONCLUSION 
The overall conclusion that emerges from present results show that 
application of anthracycline is associated with a significant increase in the 
incidence of chromosomal abnormalities. Besides inducing cell death because of 
mitotic catastrophe and induction of apoptosis, topoisomerase targeted drugs can 
induce mutations, chromosomal aberrations, sister chromatid exchanges and 
micronuclei in high frequency. Cells with these types of chromosomal 
abnormalities either may survive and carry them onward or may die due to 
apoptosis. Any surviving cell with persisting aberration holds the tendency to 
develop into secondary tumor at any time in coming future. 
In the present study among two of the anthracycline tested, Idarubicin 
showed more profound genotoxic effects in all cytogenetic assays than did 
Doxorubicin. Higher incidences of aberrations were observed including chromatid 
breaks and dicentrics. Idarubicin is a synthetic analogue of the original compound 
and carries high lipophilicity than Doxorubicin. This may enhance its uptake in the 
cells and may increase the interaction with DNA and may be attributed as the 
possible cause of higher genotoxic outcome. 
Drug induced inhibition of catalytic action of topoisomerase II may lead to 
increased recombination rates because of the loss of enzyme function. Illegitimate 
recombination, defined as a DNA rearrangement between non homologous and 
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non-specific sequence may generate deletions, duplications, insertions, 
substitutions and inversions as previously described in bacteriophage, plasmids, 
bacterial and mammalian cells. Topoisomerases have the potential for both useful 
effects, in the form of new therapeutic agents and harmful effects in the form of 
mutagenic effects. Delineating the mechanism of both will provide some very 
fruitful results. 
Alkylating agents form an important class of occupational, environmental 
and life style carcinogens and are used in some regimens as among the major 
etiological factors in leukemias. The interaction of these chemicals with DNA 
plays an important role in the initial stage of cell transformation. Taking our 
experimental results into account, both of the tested alkylating agents induced 
genetic damage, showing an important increase in sister chromatid exchanges, an 
induction of chromosomal aberrations and micronuclei in cultured lymphocytes. 
From the experimental results and earlier reports, it appears that Cisplatin is 
more potent inducer of genotoxic damage than Dacarbazine. It brings forth an 
important risk of inducing secondary neoplasm in cancer patients receiving this 
drug. DNA adducts constitute a critical early intermediate in the pathway of 
chemical carcinogenesis. Of late, a higher than expected incidence of acute 
leukemia has been observed among patients who had received high and 
cumulative doses of anticancer agents for a variety of malignant diseases including 
lung cancer. It appears so from long term monitoring of the cancer patients who 
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have received chemotherapy simply as a necessity to maximize the benefit of this 
useful drug. 
The mechanism and consequences of methylation by Dacarbazine is not 
completely known but its mutagenicity and carcinogenicity observed in 
experimental systems has given rise to the possibility that it may have similar 
activity in vivo. Although no epidemiological data on the carcinogenic effects of 
Dacarbazine alone has been published. However, a few investigators reported the 
carcinogenic effects of combined chemotherapy, including Dacarbazine. Thus 
despite having the benefit of success for cancer treatment purpose it should not be 
ignored for mutagenic effects which may persist even long after use and may 
possibly be carcinogenic. Understanding the potential synergy of alkylating agents 
at the cellular and molecular level should allow improvement of the therapeutic 
efficacy of alkylating agents without increasing the unwanted induction of 
mutations. 
Chromosomal aberrations are one of the most commonly used biomarkers 
for early detection of risk in exposed populations (Tucker et al., 1997; Liou et ai, 
1999) and are intermediate endpoint in carcinogenesis (Bonassi et al., 2000). 
Chromosomal instability persists even long after the use of anticancer drugs and 
continuous monitoring is required for the occurrence of secondary malignancies. 
Although most of the agents which induce a significant level of sister chromatid 
exchange would be carcinogenic and the level of exchange may be related to the 
degree of carcinogenicity, the probability of appearance of secondary neoplasm 
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may largely depend on viability of the cells affected by the cytotoxicity of the 
agents. 
More detailed insights into the functioning of these drugs will continue to 
provide new clues for fighting cancer and specially to fulfill the promise of 
developing other drugs that will replace them with high efficacy and reduced side 
effects. Further in vitro and in vivo experimental studies on drug and cell 
interaction studies are warranted for the benefits of patients' welfare. 
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Chromosomal Aberration and Micronucleus studies of two 
topoisomerase (II) targeting anthracyclines 
ABSTRACT 
Anthracycline antibiotics are widely used in cancer chemotherapy. Doxorubicin 
and Idarubicin, topoisomerase-targeting anthracyclines, were examined for their effect on 
chromosomal aberration and micronucleus induction in cultured human lymphocytes 
employing lymphocyte transformation test and cytokinesis-blocked micronucleus 
(CBMN) assay. A statistically significant dose-dependent increase in micronucleus 
frequency (p < 0.001) in binucleated cells was seen as well as a significant increase in 
chromosomal aberration frequency was also observed for both the drugs. A variety of 
aberrations were scored including terminal deletions, breaks, gaps, exchanges, fragment 
formation, ends rejoining, interstitial deletions etc. Nuclear division index was also 
calculated and showed a cell cycle delay towards higher doses. A number of necrotic and 
apoptotic cells were also observed at higher concentrations. This confirms the two drugs 
to be clastogenic and aneugenic. 
Keywords: Doxorubicin, Idarubicin, Chromosomal aberration assay, CBMN assay. 
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Dacarbiizinc is an antiiunior dmg liscd with considerable success in Uie chemotherapy of a number 
01 neoplasias, panicukuly advanced dis.seniinated niehinonia, soft tissue sarcomas and Hodukin'. 
disease. \n aurcnl experimenlal exercise, it was tested for observing the genomic instabiiiiv of 
peripheral blood lymphocytes in-vitro employing lymphocyte transformation test. Numerous 
cytogenetic parameters were observ-ed viz chromosomal aberration assay, Micronucieus assay 
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i^ ^LJMN) assay Various types ofchromosomal aberrations were observed with dose dependent 
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lieciuency was accompanied by decline in replication indices. Micronucieus frequency w;,s also 
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cuid slKnved a ceil c> cle dela\ tou ards higher doses. These obserN'ations confimi negative genomic 
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tumor lomiation and above mentioned parameters have extensively been used as biomaikers in 
cancer studies, nius a siifei) inspection of the patients should be takcii into account even loi.a time 
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Chromosomes 
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Chemotherapeutic drugs, besides targeting tumor cells, also interact 
with normally dividing cells of the body, which may cause darnage to 
genetic material. These days, genotoxicity is of speciaUnteres due to 
high risk of inducing secondary malignancies. An '"^^eased °ccurrence 
of chromosomal aberrations is related to the " ' f ^ ^ d n s k of cancer 
Present work is concentrated on the assessment of 9 e " ° ' o f "V <?"f^ «^ ,^ 
by two anticancer drugs, Idanibicin and Cisplatin using two dtoent 
assay systems, lymphocyte transfomiation test and cytokinesis blocked 
micronudeus assay (CBMN). Idarubicin, an anthracyc ne, is recom-
mended for the cure of hematological malignancies, " h f cisplatin, an 
alkylating agent, is given for the treatment of ovarian, "adder and os-
teogenic sarcoma cancers. Various aberrations were scored that in-
clude gaps, breaks, exchanges, fragment formation, ends re|0,ning 
terminal deletions, interstitial deletions etc. About 3-4 percent of al the 
cells were showing multiple anomalies, cytokinesis-blocked micronudeus 
assay not only provides assessment of chromosoma breakage and 
loss but also spots chromosomal rearrangements (n"cle°plasm,c 
bridges), necrosis and apoptosis. On the whole, a signrficant increase 
was obseived in the genotoxidty studies expenmented « ' * both the 
drugs. Further studies are needed to elucidate whether any of the chro-
mosomal aberrations observed can participate in the induction of sec-
ondary neoplasm. . , . . . . ,.,„ 
Keywords: Genotoxicity. Chromosomal aberrations, idarubicin, asplatin. 
CBMN. 
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